Payload Information
General Information of This Payload
| Payload ID | PAY0LQKZE |
|||||
|---|---|---|---|---|---|---|
| Name | Vincristine (VCR) |
|||||
| Synonyms |
Vincristine (VCR)
Click to Show/Hide
|
|||||
| Formula | C46H56N4O10 |
|||||
| Isosmiles | CC[C@@]1(C[C@@H]2C[C@@](C3=C(CCN(C2)C1)C4=CC=CC=C4N3)(C5=C(C=C6C(=C5)[C@]78CCN9[C@H]7[C@@](C=CC9)([C@H]([C@@]([C@@H]8N6C=O)(C(=O)OC)O)OC(=O)C)CC)OC)C(=O)OC)O |
|||||
| PubChem CID | ||||||
| InChI |
InChI=1S/C46H56N4O10/c1-7-42(55)22-28-23-45(40(53)58-5,36-30(14-18-48(24-28)25-42)29-12-9-10-13-33(29)47-36)32-20-31-34(21-35(32)57-4)50(26-51)38-44(31)16-19-49-17-11-15-43(8-2,37(44)49)39(60-27(3)52)46(38,56)41(54)59-6/h9-13,15,20-21,26,28,37-39,47,55-56H,7-8,14,16-19,22-25H2,1-6H3/t28-,37+,38-,39-,42+,43-,44-,45+,46+/m1/s1
|
|||||
| InChIKey |
OGWKCGZFUXNPDA-XQKSVPLYSA-N
|
|||||
| Pharmaceutical Properties | Molecule Weight |
824.972 |
Polar area |
171.17 |
||
Complexity |
2251.066164 |
xlogp Value |
3.5175 |
|||
Heavy Count |
60 |
Rot Bonds |
8 |
|||
Hbond acc |
12 |
Hbond Donor |
3 |
|||
The activity data of This Payload
| Standard Type | Value | Units | Cell line | Disease Model | Cell line ID | Reference |
|---|---|---|---|---|---|---|
| Cell-based Percent Inhibition (%) | -0.39 | % | Undisclosed | Undisclosed | Undisclosed | |
| Cell-based Percent Inhibition (%) | -1.83 | % | Undisclosed | Undisclosed | Undisclosed | |
| Cell-based Percent Inhibition (%) | -14.43 | % | Undisclosed | Undisclosed | Undisclosed | |
| Cell-based Percent Inhibition (%) | -17 | % | Undisclosed | Undisclosed | Undisclosed | |
| Cell-based Percent Inhibition (%) | -36 | % | Undisclosed | Undisclosed | Undisclosed | |
| Cell-based Percent Inhibition (%) | -44 | % | Undisclosed | Undisclosed | Undisclosed | |
| Tumor Growth Inhibition (TGI) | -470 | % |
Cancer cells
|
Multiple myeloma, Plasma cell myeloma
|
Undisclosed | |
| Tumor Growth Inhibition (TGI) | -470 | % |
Cancer cells
|
Multiple myeloma, Plasma cell myeloma
|
Undisclosed | |
| Tumor Growth Inhibition (TGI) | -480 | % |
Cancer cells
|
Multiple myeloma, Plasma cell myeloma
|
Undisclosed | |
| Tumor Growth Inhibition (TGI) | -480 | % |
NSCLC cells
|
Multiple myeloma, Plasma cell myeloma
|
Undisclosed | |
| Tumor Growth Inhibition (TGI) | -500 | % | Undisclosed | Undisclosed | Undisclosed | |
| Tumor Growth Inhibition (TGI) | -510 | % |
Cancer cells
|
Multiple myeloma, Plasma cell myeloma
|
Undisclosed | |
| Tumor Growth Inhibition (TGI) | -510 | % |
Cancer cells
|
Multiple myeloma, Plasma cell myeloma
|
Undisclosed | |
| Tumor Growth Inhibition (TGI) | -520 | % |
Cancer cells
|
Multiple myeloma, Plasma cell myeloma
|
Undisclosed | |
| Tumor Growth Inhibition (TGI) | -520 | % |
Cancer cells
|
Multiple myeloma, Plasma cell myeloma
|
Undisclosed | |
| Tumor Growth Inhibition (TGI) | -540 | % |
Cancer cells
|
Multiple myeloma, Plasma cell myeloma
|
Undisclosed | |
| Cell-based Percent Inhibition (%) | -6.71 | % | Undisclosed | Undisclosed | Undisclosed | |
| Tumor Growth Inhibition (TGI) | 0 | % |
Cancer cells
|
Multiple myeloma, Plasma cell myeloma
|
Undisclosed | |
| Cellular activity | 0 | % |
Cancer cells
|
Multiple myeloma, Plasma cell myeloma
|
Undisclosed | |
| Cellular activity | 0 | % |
Cancer cells
|
Multiple myeloma, Plasma cell myeloma
|
Undisclosed | |
| Cellular activity | 0 | % |
Cancer cells
|
Multiple myeloma, Plasma cell myeloma
|
Undisclosed | |
| Cellular activity | 0 | % |
Cancer cells
|
Multiple myeloma, Plasma cell myeloma
|
Undisclosed | |
| Cellular activity | 0 | % |
Cancer cells
|
Multiple myeloma, Plasma cell myeloma
|
Undisclosed | |
| Cellular activity | 0 | % |
Cancer cells
|
Multiple myeloma, Plasma cell myeloma
|
Undisclosed | |
| Half Maximal Inhibitory Concentration (IC50) | 0.00063 | ug.mL-1 |
MOLT-4 cells
|
Adult T acute lymphoblastic leukemia
|
||
| Half Maximal Inhibitory Concentration (IC50) | 0.0007 | ug.mL-1 |
Cancer cells
|
Multiple myeloma, Plasma cell myeloma
|
Undisclosed | |
| Half Maximal Inhibitory Concentration (IC50) | 0.003 | ug.mL-1 |
HEp-2 cells
|
Laryngeal carcinoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 0.003 | ppm | Undisclosed | Undisclosed | Undisclosed | |
| Half Maximal Inhibitory Concentration (IC50) | 0.0031 | ug.mL-1 |
Jurkat cells
|
Childhood T acute lymphoblastic leukemia, Precursor T-cell acute lymphoblastic leukemia
|
||
| Median Effective Dose (ED50) | 0.004 | ug ml-1 |
A549 cells
|
Lung adenocarcinoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 0.007 | ug.mL-1 |
KB cells
|
Human papillomavirus-related endocervical adenocarcinoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 0.008 | ug.mL-1 |
HL-60 cells
|
Acute myeloblastic leukemia with maturation, Adult acute myeloid leukemia with maturation
|
||
| Median Effective Dose (ED50) | 0.01 | ug ml-1 |
MCF-7 cells
|
Invasive breast carcinoma of no special type
|
||
| Median Effective Dose (ED50) | 0.01 | ug ml-1 |
PC-3 cells
|
Prostate carcinoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 0.01 | ug.mL-1 |
PA-1 cells
|
Ovarian mixed germ cell tumor
|
||
| Half Maximal Inhibitory Concentration (IC50) | 0.014 | ug.mL-1 |
HeLa cells
|
Human papillomavirus-related endocervical adenocarcinoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 0.014 | ug.mL-1 |
KB cells
|
Human papillomavirus-related endocervical adenocarcinoma
|
||
| Median Effective Dose (ED50) | 0.015 | ug ml-1 |
KB cells
|
Human papillomavirus-related endocervical adenocarcinoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 0.02 | ug.mL-1 |
KB cells
|
Human papillomavirus-related endocervical adenocarcinoma
|
||
| Median Effective Dose (ED50) | 0.02 | ug ml-1 |
HCT-8 cells
|
Ileocecal adenocarcinoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 0.025 | ug.mL-1 |
CCRF-CEM cells
|
T acute lymphoblastic leukemia
|
||
| Half Maximal Inhibitory Concentration (IC50) | 0.025 | ug.mL-1 | Undisclosed | Undisclosed | Undisclosed | |
| Half Maximal Inhibitory Concentration (IC50) | 0.04 | ug.mL-1 |
NCI-H292 cells
|
Lung mucoepidermoid carcinoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 0.042 | ug.mL-1 |
HepG2 cells
|
Hepatoblastoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 0.05 | ug.mL-1 |
MCF-7 cells
|
Invasive breast carcinoma of no special type
|
||
| Half Maximal Inhibitory Concentration (IC50) | 0.05 | ug.mL-1 |
HeLa cells
|
Human papillomavirus-related endocervical adenocarcinoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 0.051 | ug.mL-1 |
HeLa cells
|
Human papillomavirus-related endocervical adenocarcinoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 0.06 | ug.mL-1 |
CCRF-CEM cells
|
T acute lymphoblastic leukemia
|
||
| Half Maximal Inhibitory Concentration (IC50) | 0.066 | ug.mL-1 |
BGC-823 cells
|
Stomach adenocarcinoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 0.15 | ug.mL-1 |
MCF-7 cells
|
Invasive breast carcinoma of no special type
|
||
| Cellular activity | 0.2 | % |
KB cells
|
Human papillomavirus-related endocervical adenocarcinoma
|
||
| Cellular activity | 0.2 | % |
KB cells
|
Human papillomavirus-related endocervical adenocarcinoma
|
||
| Cellular activity | 0.2 | % |
KB cells
|
Human papillomavirus-related endocervical adenocarcinoma
|
||
| Cellular activity | 0.2 | % |
KB cells
|
Human papillomavirus-related endocervical adenocarcinoma
|
||
| Cellular activity | 0.2 | % |
KB cells
|
Human papillomavirus-related endocervical adenocarcinoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 0.25 | ug.mL-1 |
KB cells
|
Human papillomavirus-related endocervical adenocarcinoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 0.46 | ug.mL-1 |
COLO 320DM cells
|
Colon adenocarcinoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 0.46 | ug.mL-1 |
KB cells
|
Human papillomavirus-related endocervical adenocarcinoma
|
||
| Cellular activity | 0.5 | % |
A549 cells
|
Lung adenocarcinoma
|
||
| Cellular activity | 0.5 | % |
KB cells
|
Human papillomavirus-related endocervical adenocarcinoma
|
||
| Cellular activity | 0.5 | % |
KB cells
|
Human papillomavirus-related endocervical adenocarcinoma
|
||
| Cellular activity | 0.5 | % |
KB cells
|
Human papillomavirus-related endocervical adenocarcinoma
|
||
| Cellular activity | 0.5 | % |
OVCAR-3 cells
|
High grade ovarian serous adenocarcinoma
|
||
| Cellular activity | 0.6 | % |
Cancer cells
|
Multiple myeloma, Plasma cell myeloma
|
Undisclosed | |
| Cellular activity | 0.9 | % |
Cancer cells
|
Multiple myeloma, Plasma cell myeloma
|
Undisclosed | |
| Cellular activity | 1 | % |
KB cells
|
Human papillomavirus-related endocervical adenocarcinoma
|
||
| Cellular activity | 1 | % |
KB cells
|
Human papillomavirus-related endocervical adenocarcinoma
|
||
| Cellular activity | 1 | % |
KB cells
|
Human papillomavirus-related endocervical adenocarcinoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 1 | ug.mL-1 |
PA-1 cells
|
Ovarian mixed germ cell tumor
|
||
| Half Maximal Inhibitory Concentration (IC50) | 1.05 | ug.mL-1 |
KB cells
|
Human papillomavirus-related endocervical adenocarcinoma
|
||
| Cell-based Percent Inhibition (%) | 1.09 | % |
Vero C1008 cells
|
Normal
|
||
| Cell-based Percent Inhibition (%) | 1.09 | % |
Vero C1008 cells
|
Normal
|
||
| Half Maximal Inhibitory Concentration (IC50) | 1.1 | ug.mL-1 |
Vero cells
|
Normal
|
||
| Cellular activity | 1.2 | % |
Cancer cells
|
Multiple myeloma, Plasma cell myeloma
|
Undisclosed | |
| Median Effective Dose (ED50) | 1.3 | ug ml-1 |
KB cells
|
Human papillomavirus-related endocervical adenocarcinoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 1.37 | ug.mL-1 |
Cancer cells
|
Multiple myeloma, Plasma cell myeloma
|
Undisclosed | |
| Half Maximal Inhibitory Concentration (IC50) | 1.42 | ug.mL-1 |
WRL68 cells
|
Embryonic hepatoma
|
||
| Cell-based Percent Inhibition (%) | 1.43 | % |
Vero C1008 cells
|
Normal
|
||
| Cell-based Percent Inhibition (%) | 1.43 | % |
Vero C1008 cells
|
Normal
|
||
| Half Maximal Inhibitory Concentration (IC50) | 1.5 | ug.mL-1 |
COLO 320DM cells
|
Colon adenocarcinoma
|
||
| Cellular activity | 1.5 | day | Undisclosed | Undisclosed | Undisclosed | |
| Cell-based Percent Inhibition (%) | 1.62 | % | Undisclosed | Undisclosed | Undisclosed | |
| Cell-based Percent Inhibition (%) | 1.69 | % | Undisclosed | Undisclosed | Undisclosed | |
| Cellular activity | 10 | % |
CHO cells
|
Normal
|
||
| Cell-based Percent Inhibition (%) | 10.9 | % | Undisclosed | Undisclosed | Undisclosed | |
| Cellular activity | 100 | % |
Cancer cells
|
Multiple myeloma, Plasma cell myeloma
|
Undisclosed | |
| Cellular activity | 100 | % |
Cancer cells
|
Multiple myeloma, Plasma cell myeloma
|
Undisclosed | |
| Cellular activity | 100 | % |
Cancer cells
|
Multiple myeloma, Plasma cell myeloma
|
Undisclosed | |
| Cellular activity | 100 | % |
Cancer cells
|
Multiple myeloma, Plasma cell myeloma
|
Undisclosed | |
| Cellular activity | 100 | % |
Cancer cells
|
Multiple myeloma, Plasma cell myeloma
|
Undisclosed | |
| Cellular activity | 100 | % | Undisclosed | Undisclosed | Undisclosed | |
| Cellular activity | 100 | % | Undisclosed | Undisclosed | Undisclosed | |
| Cellular activity | 100 | % | Undisclosed | Undisclosed | Undisclosed | |
| Cellular activity | 100 | % | Undisclosed | Undisclosed | Undisclosed | |
| Cellular activity | 100 | % | Undisclosed | Undisclosed | Undisclosed | |
| Cellular activity | 100 | % | Undisclosed | Undisclosed | Undisclosed | |
| Cellular activity | 11.1 | % |
KB cells
|
Human papillomavirus-related endocervical adenocarcinoma
|
||
| Cellular activity | 11.1 | % |
KB cells
|
Human papillomavirus-related endocervical adenocarcinoma
|
||
| Cellular activity | 11.1 | % |
KB cells
|
Human papillomavirus-related endocervical adenocarcinoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 11.2 | ug.mL-1 |
HL-60 cells
|
Acute myeloblastic leukemia with maturation, Adult acute myeloid leukemia with maturation
|
||
| Cellular activity | 11.7 | % |
KB cells
|
Human papillomavirus-related endocervical adenocarcinoma
|
||
| Cellular activity | 11.7 | % |
KB cells
|
Human papillomavirus-related endocervical adenocarcinoma
|
||
| Cellular activity | 11.7 | % |
KB cells
|
Human papillomavirus-related endocervical adenocarcinoma
|
||
| Cellular activity | 11.8 | % |
PLC-PRF-5 cells
|
Hepatocellular carcinoma
|
||
| Cellular activity | 112 | % |
HeLa cells
|
Human papillomavirus-related endocervical adenocarcinoma
|
||
| Cellular activity | 12.2 | % |
PLC-PRF-5 cells
|
Hepatocellular carcinoma
|
||
| Cellular activity | 12.5 | % |
HCT116 cells
|
Colon carcinoma
|
||
| Cell-based Percent Inhibition (%) | 13 | % |
HEK293 cells
|
Normal
|
||
| Cellular activity | 13.1 | % |
KB cells
|
Human papillomavirus-related endocervical adenocarcinoma
|
||
| Cellular activity | 13.1 | % |
KB cells
|
Human papillomavirus-related endocervical adenocarcinoma
|
||
| Cellular activity | 13.1 | % |
KB cells
|
Human papillomavirus-related endocervical adenocarcinoma
|
||
| Cellular activity | 13.83 | % |
HCC1428 cells
|
Breast adenocarcinoma
|
||
| Cellular activity | 138 | % |
P388/S cells
|
Leukemia
|
||
| Cellular activity | 14.29 | % |
CAL-33 cells
|
Squamous cell carcinoma of the oral tongue, Tongue squamous cell carcinoma
|
||
| Cellular activity | 14.7 | % |
SNU-398 cells
|
Hepatocellular carcinoma
|
||
| Cellular activity | 15 | % | Undisclosed | Undisclosed | Undisclosed | |
| Cellular activity | 16.43 | % |
HT-29 cells
|
Colon adenocarcinoma
|
||
| Cell-based Percent Inhibition (%) | 16.8 | % |
Vero cells
|
Normal
|
||
| Cellular activity | 16.81 | % |
Vero cells
|
Normal
|
||
| Cellular activity | 17.1 | % |
SNU-398 cells
|
Hepatocellular carcinoma
|
||
| Cellular activity | 17.13 | % |
CAL-33 cells
|
Squamous cell carcinoma of the oral tongue, Tongue squamous cell carcinoma
|
||
| Cellular activity | 17.2 | % |
KB cells
|
Human papillomavirus-related endocervical adenocarcinoma
|
||
| Cellular activity | 17.2 | % |
KB cells
|
Human papillomavirus-related endocervical adenocarcinoma
|
||
| Cellular activity | 17.2 | % |
KB cells
|
Human papillomavirus-related endocervical adenocarcinoma
|
||
| Cellular activity | 17.7 | % |
MCF-7 cells
|
Invasive breast carcinoma of no special type
|
||
| Cellular activity | 17.9 | % |
MCF-7 cells
|
Invasive breast carcinoma of no special type
|
||
| Cellular activity | 18.4 | % |
HEK293 cells
|
Normal
|
||
| Cellular activity | 2.75 | % |
MCF-7 cells
|
Invasive breast carcinoma of no special type
|
||
| Cell-based Percent Inhibition (%) | 2.79 | % | Undisclosed | Undisclosed | Undisclosed | |
| Cell-based Percent Inhibition (%) | 2.81 | % | Undisclosed | Undisclosed | Undisclosed | |
| Cellular activity | 20 | % |
Cancer cells
|
Multiple myeloma, Plasma cell myeloma
|
Undisclosed | |
| Cellular activity | 20.5 | % |
CAL-33 cells
|
Squamous cell carcinoma of the oral tongue, Tongue squamous cell carcinoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 20.74 | ug.mL-1 |
SMMC-7721 cells
|
Hepatocellular carcinoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | >200 | ug.mL-1 | Undisclosed | Undisclosed | Undisclosed | |
| Cellular activity | 21.2 | % |
PANC-1 cells
|
Pancreatic ductal adenocarcinoma
|
||
| Cellular activity | 23 | % |
HCT116 cells
|
Colon carcinoma
|
||
| Cell-based Percent Inhibition (%) | 23.25 | % |
Caco-2 cells
|
Colon adenocarcinoma
|
||
| Cellular activity | 23.45 | % |
MCF-7 cells
|
Invasive breast carcinoma of no special type
|
||
| Cellular activity | 24 | % |
KB cells
|
Human papillomavirus-related endocervical adenocarcinoma
|
||
| Cellular activity | 24 | % |
KB cells
|
Human papillomavirus-related endocervical adenocarcinoma
|
||
| Cellular activity | 24 | % |
KB cells
|
Human papillomavirus-related endocervical adenocarcinoma
|
||
| Cellular activity | 24.6 | g |
H22 cells
|
Hepatoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | >25 | ug.mL-1 |
KB cells
|
Human papillomavirus-related endocervical adenocarcinoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | >25 | ug.mL-1 |
Cancer cells
|
Multiple myeloma, Plasma cell myeloma
|
Undisclosed | |
| Cellular activity | 25.2 | % |
Cancer cells
|
Multiple myeloma, Plasma cell myeloma
|
Undisclosed | |
| Cellular activity | 25.3 | % |
HCT116 cells
|
Colon carcinoma
|
||
| Cellular activity | 25.5 | % |
Cancer cells
|
Multiple myeloma, Plasma cell myeloma
|
Undisclosed | |
| Cellular activity | 25.5 | g |
H22 cells
|
Hepatoma
|
||
| Cellular activity | 25.8 | % |
Cancer cells
|
Multiple myeloma, Plasma cell myeloma
|
Undisclosed | |
| Cellular activity | 26 | % |
KB cells
|
Human papillomavirus-related endocervical adenocarcinoma
|
||
| Cellular activity | 26 | % |
KB cells
|
Human papillomavirus-related endocervical adenocarcinoma
|
||
| Cellular activity | 26 | % |
KB cells
|
Human papillomavirus-related endocervical adenocarcinoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 26.7 | ug.mL-1 |
SMMC-7721 cells
|
Hepatocellular carcinoma
|
||
| Cellular activity | 265 | % |
PANC-1 cells
|
Pancreatic ductal adenocarcinoma
|
||
| Cellular activity | 27.7 | % |
KB cells
|
Human papillomavirus-related endocervical adenocarcinoma
|
||
| Cellular activity | 27.7 | % |
KB cells
|
Human papillomavirus-related endocervical adenocarcinoma
|
||
| Cellular activity | 27.7 | % |
KB cells
|
Human papillomavirus-related endocervical adenocarcinoma
|
||
| Cell-based Percent Inhibition (%) | 28.1 | % | Undisclosed | Undisclosed | Undisclosed | |
| Cellular activity | 28.3 | % |
KB cells
|
Human papillomavirus-related endocervical adenocarcinoma
|
||
| Cellular activity | 28.3 | % |
KB cells
|
Human papillomavirus-related endocervical adenocarcinoma
|
||
| Cellular activity | 28.3 | % |
KB cells
|
Human papillomavirus-related endocervical adenocarcinoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 28.4 | ug.mL-1 |
L02 cells
|
Human papillomavirus-related endocervical adenocarcinoma
|
||
| Cellular activity | 28.6 | % |
HCT116 cells
|
Colon carcinoma
|
||
| Cellular activity | 28.8 | % |
Cancer cells
|
Multiple myeloma, Plasma cell myeloma
|
Undisclosed | |
| Cellular activity | 283 | % |
MCF-7 cells
|
Invasive breast carcinoma of no special type
|
||
| Cellular activity | 29.1 | % |
Cancer cells
|
Multiple myeloma, Plasma cell myeloma
|
Undisclosed | |
| Cell-based Percent Inhibition (%) | 29.44 | % | Undisclosed | Undisclosed | Undisclosed | |
| Half Maximal Inhibitory Concentration (IC50) | 2930 | ug.mL-1 |
Cancer cells
|
Multiple myeloma, Plasma cell myeloma
|
Undisclosed | |
| Cell-based Percent Inhibition (%) | 3.19 | % | Undisclosed | Undisclosed | Undisclosed | |
| Cell-based Percent Inhibition (%) | 3.35 | % | Undisclosed | Undisclosed | Undisclosed | |
| Cell-based Percent Inhibition (%) | 3.9 | % |
HEK293 cells
|
Normal
|
||
| Cellular activity | 30.4 | % |
Cancer cells
|
Multiple myeloma, Plasma cell myeloma
|
Undisclosed | |
| Cell-based Percent Inhibition (%) | 30.58 | % | Undisclosed | Undisclosed | Undisclosed | |
| Tumor Growth Inhibition (TGI) | 31 | % |
H22 cells
|
Hepatoma
|
||
| Cellular activity | 31.6 | % |
HCT116 cells
|
Colon carcinoma
|
||
| Cell-based Percent Inhibition (%) | ~35 | % |
Cancer cells
|
Multiple myeloma, Plasma cell myeloma
|
Undisclosed | |
| Cellular activity | 35.9 | % |
HCT116 cells
|
Colon carcinoma
|
||
| Cellular activity | 39.1 | % |
HEK293 cells
|
Normal
|
||
| Cellular activity | 4 | % |
HCT116 cells
|
Colon carcinoma
|
||
| Cellular activity | 4 | % |
HCC1428 cells
|
Breast adenocarcinoma
|
||
| Cellular activity | 4.15 | % |
HCC1428 cells
|
Breast adenocarcinoma
|
||
| Cellular activity | 4.65 | % |
HT-29 cells
|
Colon adenocarcinoma
|
||
| Cellular activity | 4.8 | % |
KB cells
|
Human papillomavirus-related endocervical adenocarcinoma
|
||
| Cellular activity | 4.8 | % |
KB cells
|
Human papillomavirus-related endocervical adenocarcinoma
|
||
| Cellular activity | 4.8 | % |
KB cells
|
Human papillomavirus-related endocervical adenocarcinoma
|
||
| Cellular activity | 40 | % |
CHO cells
|
Normal
|
||
| Cellular activity | 42 | % | Undisclosed | Undisclosed | Undisclosed | |
| Cellular activity | 45.2 | % |
A549 cells
|
Lung adenocarcinoma
|
||
| Cellular activity | 45.2 | % |
OVCAR-3 cells
|
High grade ovarian serous adenocarcinoma
|
||
| Cellular activity | 46 | % |
NCI-H157 cells
|
Non-small cell lung carcinoma
|
||
| Cellular activity | 46.8 | % |
A549 cells
|
Lung adenocarcinoma
|
||
| Cellular activity | 46.8 | % |
OVCAR-3 cells
|
High grade ovarian serous adenocarcinoma
|
||
| Cellular activity | 47 | % |
NCI-H157 cells
|
Non-small cell lung carcinoma
|
||
| Tumor Growth Inhibition (TGI) | 470 | % |
Cancer cells
|
Multiple myeloma, Plasma cell myeloma
|
Undisclosed | |
| Tumor Growth Inhibition (TGI) | 470 | % |
Cancer cells
|
Multiple myeloma, Plasma cell myeloma
|
Undisclosed | |
| Tumor Growth Inhibition (TGI) | 480 | % |
Leukemia cells
|
Multiple myeloma, Plasma cell myeloma
|
Undisclosed | |
| Tumor Growth Inhibition (TGI) | 480 | % |
NSCLC cells
|
Multiple myeloma, Plasma cell myeloma
|
Undisclosed | |
| Cellular activity | 49.2 | % |
CAL-33 cells
|
Squamous cell carcinoma of the oral tongue, Tongue squamous cell carcinoma
|
||
| Cellular activity | 5.1 | % |
MCF-7 cells
|
Invasive breast carcinoma of no special type
|
||
| Half Maximal Inhibitory Concentration (IC50) | 5.4 | ug.mL-1 |
Cancer cells
|
Multiple myeloma, Plasma cell myeloma
|
Undisclosed | |
| Cellular activity | 5.9 | % |
KB cells
|
Human papillomavirus-related endocervical adenocarcinoma
|
||
| Cellular activity | 5.9 | % |
KB cells
|
Human papillomavirus-related endocervical adenocarcinoma
|
||
| Cellular activity | 5.9 | % |
KB cells
|
Human papillomavirus-related endocervical adenocarcinoma
|
||
| Cellular activity | 5.97 | % |
HT-29 cells
|
Colon adenocarcinoma
|
||
| Cell-based Percent Inhibition (%) | ~50 | % |
MOLM-13 cells
|
Acute monoblastic/monocytic leukemia, Adult acute monocytic leukemia, Myelodysplastic syndrome
|
||
| Cell-based Percent Inhibition (%) | 50 | % | Undisclosed | Undisclosed | Undisclosed | |
| Tumor Growth Inhibition (TGI) | 500 | % |
Cancer cells
|
Multiple myeloma, Plasma cell myeloma
|
Undisclosed | |
| Tumor Growth Inhibition (TGI) | 51 | % |
Cancer cells
|
Multiple myeloma, Plasma cell myeloma
|
Undisclosed | |
| Tumor Growth Inhibition (TGI) | 510 | % |
Melanoma cells
|
Multiple myeloma, Plasma cell myeloma
|
Undisclosed | |
| Tumor Growth Inhibition (TGI) | 510 | % |
Cancer cells
|
Multiple myeloma, Plasma cell myeloma
|
Undisclosed | |
| Tumor Growth Inhibition (TGI) | 520 | % |
Cancer cells
|
Multiple myeloma, Plasma cell myeloma
|
Undisclosed | |
| Tumor Growth Inhibition (TGI) | 520 | % |
Cancer cells
|
Multiple myeloma, Plasma cell myeloma
|
Undisclosed | |
| Cellular activity | 53.7 | % |
KB cells
|
Human papillomavirus-related endocervical adenocarcinoma
|
||
| Cellular activity | 53.7 | % |
KB cells
|
Human papillomavirus-related endocervical adenocarcinoma
|
||
| Cellular activity | 53.7 | % |
KB cells
|
Human papillomavirus-related endocervical adenocarcinoma
|
||
| Cellular activity | 54.6 | % |
MCF-7 cells
|
Invasive breast carcinoma of no special type
|
||
| Tumor Growth Inhibition (TGI) | 540 | % |
Cancer cells
|
Multiple myeloma, Plasma cell myeloma
|
Undisclosed | |
| Cellular activity | 56.1 | % |
MCF-7 cells
|
Invasive breast carcinoma of no special type
|
||
| Cell-based Percent Inhibition (%) | 59.8 | % |
HEK293 cells
|
Normal
|
||
| Cellular activity | 6.5 | % |
KB cells
|
Human papillomavirus-related endocervical adenocarcinoma
|
||
| Cellular activity | 6.5 | % |
KB cells
|
Human papillomavirus-related endocervical adenocarcinoma
|
||
| Cellular activity | 6.5 | % |
KB cells
|
Human papillomavirus-related endocervical adenocarcinoma
|
||
| Cellular activity | 6.5 | % |
KB cells
|
Human papillomavirus-related endocervical adenocarcinoma
|
||
| Cellular activity | 6.96 | % |
HCC1428 cells
|
Breast adenocarcinoma
|
||
| Cellular activity | 60 | % |
Astrocyte cells
|
Multiple myeloma, Plasma cell myeloma
|
Undisclosed | |
| Tumor Growth Inhibition (TGI) | 61 | % |
H22 cells
|
Hepatoma
|
||
| Cellular activity | 61.2 | % |
KB cells
|
Human papillomavirus-related endocervical adenocarcinoma
|
||
| Cellular activity | 61.2 | % |
KB cells
|
Human papillomavirus-related endocervical adenocarcinoma
|
||
| Cellular activity | 61.2 | % |
KB cells
|
Human papillomavirus-related endocervical adenocarcinoma
|
||
| Cellular activity | 64.1 | % |
PANC-1 cells
|
Pancreatic ductal adenocarcinoma
|
||
| Cellular activity | 64.5 | % |
KB cells
|
Human papillomavirus-related endocervical adenocarcinoma
|
||
| Cellular activity | 64.5 | % |
KB cells
|
Human papillomavirus-related endocervical adenocarcinoma
|
||
| Cellular activity | 64.5 | % |
KB cells
|
Human papillomavirus-related endocervical adenocarcinoma
|
||
| Cellular activity | 64.5 | % |
SNU-398 cells
|
Hepatocellular carcinoma
|
||
| Cell-based Percent Inhibition (%) | 65.1 | % | Undisclosed | Undisclosed | Undisclosed | |
| Cellular activity | 65.8 | % |
KB cells
|
Human papillomavirus-related endocervical adenocarcinoma
|
||
| Cellular activity | 65.8 | % |
KB cells
|
Human papillomavirus-related endocervical adenocarcinoma
|
||
| Cellular activity | 65.8 | % |
KB cells
|
Human papillomavirus-related endocervical adenocarcinoma
|
||
| Half Maximal Growth Inhibitory Concentration (GI50) | 650 | % |
Cancer cells
|
Multiple myeloma, Plasma cell myeloma
|
Undisclosed | |
| Half Maximal Growth Inhibitory Concentration (GI50) | 650 | % |
Cancer cells
|
Multiple myeloma, Plasma cell myeloma
|
Undisclosed | |
| Half Maximal Growth Inhibitory Concentration (GI50) | 650 | % |
Cancer cells
|
Multiple myeloma, Plasma cell myeloma
|
Undisclosed | |
| Half Maximal Growth Inhibitory Concentration (GI50) | 660 | % |
NSCLC cells
|
Multiple myeloma, Plasma cell myeloma
|
Undisclosed | |
| Half Maximal Growth Inhibitory Concentration (GI50) | 670 | % |
Cancer cells
|
Multiple myeloma, Plasma cell myeloma
|
Undisclosed | |
| Cellular activity | 68.4 | % |
PLC-PRF-5 cells
|
Hepatocellular carcinoma
|
||
| Half Maximal Growth Inhibitory Concentration (GI50) | 680 | % |
Melanoma cells
|
Multiple myeloma, Plasma cell myeloma
|
Undisclosed | |
| Cellular activity | 69.8 | % |
Cancer cells
|
Multiple myeloma, Plasma cell myeloma
|
Undisclosed | |
| Cellular activity | 69.8 | % |
NCI-H157 cells
|
Non-small cell lung carcinoma
|
||
| Half Maximal Growth Inhibitory Concentration (GI50) | 690 | % |
Cancer cells
|
Multiple myeloma, Plasma cell myeloma
|
Undisclosed | |
| Half Maximal Growth Inhibitory Concentration (GI50) | 690 | % |
Cancer cells
|
Multiple myeloma, Plasma cell myeloma
|
Undisclosed | |
| Median Effective Dose (ED50) | 7 | ug ml-1 |
Cancer cells
|
Multiple myeloma, Plasma cell myeloma
|
Undisclosed | |
| Cellular activity | 7.2 | % |
KB cells
|
Human papillomavirus-related endocervical adenocarcinoma
|
||
| Cellular activity | 7.2 | % |
KB cells
|
Human papillomavirus-related endocervical adenocarcinoma
|
||
| Cellular activity | 7.2 | % |
KB cells
|
Human papillomavirus-related endocervical adenocarcinoma
|
||
| Cellular activity | 7.8 | % |
MCF-7 cells
|
Invasive breast carcinoma of no special type
|
||
| Cellular activity | 7.9 | % |
A549 cells
|
Lung adenocarcinoma
|
||
| Cellular activity | 7.9 | % |
OVCAR-3 cells
|
High grade ovarian serous adenocarcinoma
|
||
| Cellular activity | >70 | % | Undisclosed | Undisclosed | Undisclosed | |
| Cellular activity | 70.9 | % |
Cancer cells
|
Multiple myeloma, Plasma cell myeloma
|
Undisclosed | |
| Cellular activity | 70.9 | % |
NCI-H157 cells
|
Non-small cell lung carcinoma
|
||
| Half Maximal Growth Inhibitory Concentration (GI50) | 700 | % |
Cancer cells
|
Multiple myeloma, Plasma cell myeloma
|
Undisclosed | |
| Half Maximal Growth Inhibitory Concentration (GI50) | 700 | % |
Leukemia cells
|
Multiple myeloma, Plasma cell myeloma
|
Undisclosed | |
| Cellular activity | 713 | a.u. | Undisclosed | Undisclosed | Undisclosed | |
| Cellular activity | 72 | % |
K562 cells
|
Blast phase chronic myelogenous leukemia, BCR-ABL1 positive, Chronic myeloid leukemia
|
||
| Cellular activity | 72.53 | % |
HT-29 cells
|
Colon adenocarcinoma
|
||
| Cellular activity | 72.6 | % |
Cancer cells
|
Multiple myeloma, Plasma cell myeloma
|
Undisclosed | |
| Cellular activity | 72.6 | % |
NCI-H157 cells
|
Non-small cell lung carcinoma
|
||
| Cellular activity | 722 | a.u. | Undisclosed | Undisclosed | Undisclosed | |
| Cellular activity | 74.5 | % |
MDA-MB-231 cells
|
Breast adenocarcinoma
|
||
| Cellular activity | 74.5 | % |
Cancer cells
|
Multiple myeloma, Plasma cell myeloma
|
Undisclosed | |
| Cellular activity | 74.5 | % |
NCI-H157 cells
|
Non-small cell lung carcinoma
|
||
| Cellular activity | 747 | a.u. | Undisclosed | Undisclosed | Undisclosed | |
| Cellular activity | 747 | a.u. | Undisclosed | Undisclosed | Undisclosed | |
| Tumor Growth Inhibition (TGI) | 75 | % |
Cancer cells
|
Multiple myeloma, Plasma cell myeloma
|
Undisclosed | |
| Tumor Growth Inhibition (TGI) | 75 | % | Undisclosed | Undisclosed | Undisclosed | |
| Tumor Growth Inhibition (TGI) | 76 | % |
Cancer cells
|
Multiple myeloma, Plasma cell myeloma
|
Undisclosed | |
| Tumor Growth Inhibition (TGI) | 77 | % |
Cancer cells
|
Multiple myeloma, Plasma cell myeloma
|
Undisclosed | |
| Cell-based Percent Inhibition (%) | 77 | % | Undisclosed | Undisclosed | Undisclosed | |
| Half Maximal Inhibitory Concentration (IC50) | 8.5 | ug.mL-1 |
WRL68 cells
|
Embryonic hepatoma
|
||
| Cellular activity | 80 | % |
Cancer cells
|
Multiple myeloma, Plasma cell myeloma
|
Undisclosed | |
| Cellular activity | 82 | % |
Sf9 cells
|
Normal
|
||
| Cellular activity | 82.17 | % |
HCC1428 cells
|
Breast adenocarcinoma
|
||
| Cellular activity | 83 | % |
P388/S cells
|
Leukemia
|
||
| Cellular activity | 83 | % |
P388/S cells
|
Leukemia
|
||
| Cell-based Percent Inhibition (%) | 83 | % | Undisclosed | Undisclosed | Undisclosed | |
| Cellular activity | 86.7 | % |
KB cells
|
Human papillomavirus-related endocervical adenocarcinoma
|
||
| Cellular activity | 86.7 | % |
KB cells
|
Human papillomavirus-related endocervical adenocarcinoma
|
||
| Cellular activity | 86.7 | % |
KB cells
|
Human papillomavirus-related endocervical adenocarcinoma
|
||
| Cell-based Percent Inhibition (%) | 87 | % | Undisclosed | Undisclosed | Undisclosed | |
| Cellular activity | 88.89 | % |
HCC1428 cells
|
Breast adenocarcinoma
|
||
| Cellular activity | 9.7 | % |
PANC-1 cells
|
Pancreatic ductal adenocarcinoma
|
||
| Cellular activity | 92.6 | % |
KB cells
|
Human papillomavirus-related endocervical adenocarcinoma
|
||
| Cellular activity | 92.6 | % |
KB cells
|
Human papillomavirus-related endocervical adenocarcinoma
|
||
| Cellular activity | 92.6 | % |
KB cells
|
Human papillomavirus-related endocervical adenocarcinoma
|
||
| Cellular activity | 93.8 | % |
KB cells
|
Human papillomavirus-related endocervical adenocarcinoma
|
||
| Cellular activity | 93.8 | % |
KB cells
|
Human papillomavirus-related endocervical adenocarcinoma
|
||
| Cellular activity | 93.8 | % |
KB cells
|
Human papillomavirus-related endocervical adenocarcinoma
|
||
| Cellular activity | 95.1 | % |
KB cells
|
Human papillomavirus-related endocervical adenocarcinoma
|
||
| Cellular activity | 95.1 | % |
KB cells
|
Human papillomavirus-related endocervical adenocarcinoma
|
||
| Cellular activity | 95.1 | % |
KB cells
|
Human papillomavirus-related endocervical adenocarcinoma
|
||
| Cellular activity | 96 | % |
P388/S cells
|
Leukemia
|
||
| Cellular activity | 98 | % |
HeLa cells
|
Human papillomavirus-related endocervical adenocarcinoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 0.01 | nM |
HT-29 cells
|
Colon adenocarcinoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 0.02 | nM |
MES-SA/Dx5 cells
|
Uterine sarcoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 0.1 | nM |
K562 cells
|
Blast phase chronic myelogenous leukemia, BCR-ABL1 positive, Chronic myeloid leukemia
|
||
| Half Maximal Inhibitory Concentration (IC50) | 0.1 | nM |
ARO cells
|
Anaplastic thyroid carcinoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | <0.1 | nM |
ARO cells
|
Anaplastic thyroid carcinoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 0.13 | nM |
NCI-H460 cells
|
Lung large cell carcinoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | <0.13 | nM |
SNU-398 cells
|
Hepatocellular carcinoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 0.17 | nM |
CCRF-CEM cells
|
T acute lymphoblastic leukemia
|
||
| Half Maximal Inhibitory Concentration (IC50) | 0.2 | nM |
KB cells
|
Human papillomavirus-related endocervical adenocarcinoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 0.2 | nM |
Cancer cells
|
Multiple myeloma, Plasma cell myeloma
|
Undisclosed | |
| Half Maximal Inhibitory Concentration (IC50) | 0.21 | nM |
KB cells
|
Human papillomavirus-related endocervical adenocarcinoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 0.29 | nM |
MDA-MB-435 cells
|
Amelanotic melanoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 0.3 | nM |
Cancer cells
|
Multiple myeloma, Plasma cell myeloma
|
Undisclosed | |
| Half Maximal Inhibitory Concentration (IC50) | 0.3 | nM |
ARO cells
|
Anaplastic thyroid carcinoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 0.3 | nM | Undisclosed | Undisclosed | Undisclosed | |
| Half Maximal Inhibitory Concentration (IC50) | 0.4 | nM |
MDA-MB-468 cells
|
Breast adenocarcinoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 0.4 | nM |
KB cells
|
Human papillomavirus-related endocervical adenocarcinoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 0.4 | nM |
KB cells
|
Human papillomavirus-related endocervical adenocarcinoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 0.4 | nM |
KB cells
|
Human papillomavirus-related endocervical adenocarcinoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 0.4 | nM | Undisclosed | Undisclosed | Undisclosed | |
| Half Maximal Inhibitory Concentration (IC50) | 0.6 | nM |
MCF-7 cells
|
Invasive breast carcinoma of no special type
|
||
| Half Maximal Inhibitory Concentration (IC50) | 0.6 | nM |
MCF-7 cells
|
Invasive breast carcinoma of no special type
|
||
| Half Maximal Inhibitory Concentration (IC50) | 0.6 | nM |
KB cells
|
Human papillomavirus-related endocervical adenocarcinoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 0.63 | nM |
MDA-MB-435 cells
|
Amelanotic melanoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 0.65 | nM |
KB cells
|
Human papillomavirus-related endocervical adenocarcinoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 0.72 | nM |
KB cells
|
Human papillomavirus-related endocervical adenocarcinoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 0.73 | nM |
L1210 cells
|
Lymphoblastic leukemia
|
||
| Half Maximal Inhibitory Concentration (IC50) | 0.8 | nM |
KB cells
|
Human papillomavirus-related endocervical adenocarcinoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 0.8 | nM | Undisclosed | Undisclosed | Undisclosed | |
| Half Maximal Inhibitory Concentration (IC50) | 0.84 | nM |
MCF-7 cells
|
Invasive breast carcinoma of no special type
|
||
| Half Maximal Inhibitory Concentration (IC50) | 0.87 | nM |
HL-60 cells
|
Acute myeloblastic leukemia with maturation, Adult acute myeloid leukemia with maturation
|
||
| Half Maximal Inhibitory Concentration (IC50) | 0.87 | nM |
KB cells
|
Human papillomavirus-related endocervical adenocarcinoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 0.9 | nM |
A2780 cells
|
Ovarian endometrioid adenocarcinoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 0.9 | nM |
KB cells
|
Human papillomavirus-related endocervical adenocarcinoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 0.9 | nM |
KB cells
|
Human papillomavirus-related endocervical adenocarcinoma
|
||
| Half Maximal Growth Inhibitory Concentration (GI50) | 1 | nM |
HCT116 cells
|
Colon carcinoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 1 | nM |
HeLa cells
|
Human papillomavirus-related endocervical adenocarcinoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 1 | nM |
HT-29 cells
|
Colon adenocarcinoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 1 | nM |
KB cells
|
Human papillomavirus-related endocervical adenocarcinoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 1 | nM |
Cancer cells
|
Multiple myeloma, Plasma cell myeloma
|
Undisclosed | |
| Half Maximal Effective Concentration (EC50) | >1 | nM | Undisclosed | Undisclosed | Undisclosed | |
| Half Maximal Inhibitory Concentration (IC50) | 1 | nM | Undisclosed | Undisclosed | Undisclosed | |
| Half Maximal Inhibitory Concentration (IC50) | 1.12 | nM |
DU145 cells
|
Prostate carcinoma
|
||
| Half Maximal Growth Inhibitory Concentration (GI50) | 1.14 | nM |
PC-6 cells
|
Small cell lung carcinoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 1.18 | nM |
Cancer cells
|
Multiple myeloma, Plasma cell myeloma
|
Undisclosed | |
| Half Maximal Inhibitory Concentration (IC50) | 1.2 | nM |
KB cells
|
Human papillomavirus-related endocervical adenocarcinoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 1.2 | nM |
786-O cells
|
Renal cell carcinoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 1.2 | nM |
Cancer cells
|
Multiple myeloma, Plasma cell myeloma
|
Undisclosed | |
| Half Maximal Inhibitory Concentration (IC50) | 1.2 | nM |
Cancer cells
|
Multiple myeloma, Plasma cell myeloma
|
Undisclosed | |
| Half Maximal Inhibitory Concentration (IC50) | 1.2 | nM |
Cancer cells
|
Multiple myeloma, Plasma cell myeloma
|
Undisclosed | |
| Half Maximal Inhibitory Concentration (IC50) | 1.2 | nM |
P388 cells
|
Lymphoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 1.302 | nM |
MV4-11 cells
|
Childhood acute monocytic leukemia
|
||
| Half Maximal Growth Inhibitory Concentration (GI50) | 1.5 | nM |
MCF-7 cells
|
Invasive breast carcinoma of no special type
|
||
| Half Maximal Inhibitory Concentration (IC50) | 1.5 | nM |
Cancer cells
|
Multiple myeloma, Plasma cell myeloma
|
Undisclosed | |
| Half Maximal Inhibitory Concentration (IC50) | 1.5 | nM |
Cancer cells
|
Multiple myeloma, Plasma cell myeloma
|
Undisclosed | |
| Half Maximal Inhibitory Concentration (IC50) | 1.5 | nM |
Cancer cells
|
Multiple myeloma, Plasma cell myeloma
|
Undisclosed | |
| Half Maximal Inhibitory Concentration (IC50) | 1.51 | nM |
Cancer cells
|
Multiple myeloma, Plasma cell myeloma
|
Undisclosed | |
| Half Maximal Inhibitory Concentration (IC50) | 1.6 | nM |
MDA-MB-231 cells
|
Breast adenocarcinoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 1.63 | nM |
Cancer cells
|
Multiple myeloma, Plasma cell myeloma
|
Undisclosed | |
| Half Maximal Growth Inhibitory Concentration (GI50) | 1.7 | nM |
HeLa cells
|
Human papillomavirus-related endocervical adenocarcinoma
|
||
| Half Maximal Growth Inhibitory Concentration (GI50) | 1.86 | nM |
KB cells
|
Human papillomavirus-related endocervical adenocarcinoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 10 | nM |
MCF-7 cells
|
Invasive breast carcinoma of no special type
|
||
| Half Maximal Inhibitory Concentration (IC50) | 10 | nM |
B16-F10 cells
|
Mouse melanoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 10 | nM |
HT-29 cells
|
Colon adenocarcinoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 10 | nM |
HT-29 cells
|
Colon adenocarcinoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 10 | nM |
KB cells
|
Human papillomavirus-related endocervical adenocarcinoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 10 | nM |
OVCAR-3 cells
|
High grade ovarian serous adenocarcinoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 10 | nM |
IGROV-1 cells
|
Endometrioid carcinoma of ovary, Ovarian endometrioid adenocarcinoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 10 | nM |
Cancer cells
|
Multiple myeloma, Plasma cell myeloma
|
Undisclosed | |
| Half Maximal Inhibitory Concentration (IC50) | 10 | nM |
Cancer cells
|
Multiple myeloma, Plasma cell myeloma
|
Undisclosed | |
| Half Maximal Inhibitory Concentration (IC50) | 10 | nM |
SiHa cells
|
Cervical squamous cell carcinoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 10 | nM |
SNU-423 cells
|
Hepatocellular carcinoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 10.3 | nM |
SMMC-7721 cells
|
Hepatocellular carcinoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 100 | nM |
HepG2 cells
|
Hepatoblastoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | >100 | nM |
HepG2 cells
|
Hepatoblastoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 100 | nM |
HT-29 cells
|
Colon adenocarcinoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 100 | nM |
Cancer cells
|
Multiple myeloma, Plasma cell myeloma
|
Undisclosed | |
| Half Maximal Growth Inhibitory Concentration (GI50) | 100 | nM |
Cancer cells
|
Multiple myeloma, Plasma cell myeloma
|
Undisclosed | |
| Half Maximal Inhibitory Concentration (IC50) | 100 | nM |
Cancer cells
|
Multiple myeloma, Plasma cell myeloma
|
Undisclosed | |
| Half Maximal Growth Inhibitory Concentration (GI50) | 100 | nM |
Cancer cells
|
Multiple myeloma, Plasma cell myeloma
|
Undisclosed | |
| Half Maximal Growth Inhibitory Concentration (GI50) | 100 | nM |
Cancer cells
|
Multiple myeloma, Plasma cell myeloma
|
Undisclosed | |
| Half Maximal Growth Inhibitory Concentration (GI50) | 100 | nM |
Cancer cells
|
Multiple myeloma, Plasma cell myeloma
|
Undisclosed | |
| Half Maximal Inhibitory Concentration (IC50) | 100 | nM |
Cancer cells
|
Multiple myeloma, Plasma cell myeloma
|
Undisclosed | |
| Half Maximal Growth Inhibitory Concentration (GI50) | 100 | nM |
Cancer cells
|
Multiple myeloma, Plasma cell myeloma
|
Undisclosed | |
| Half Maximal Growth Inhibitory Concentration (GI50) | 100 | nM |
Cancer cells
|
Multiple myeloma, Plasma cell myeloma
|
Undisclosed | |
| Half Maximal Growth Inhibitory Concentration (GI50) | 100 | nM |
Cancer cells
|
Multiple myeloma, Plasma cell myeloma
|
Undisclosed | |
| Half Maximal Inhibitory Concentration (IC50) | 100 | nM |
Cancer cells
|
Multiple myeloma, Plasma cell myeloma
|
Undisclosed | |
| Median Effective Dose (ED50) | >100 | nM |
Cancer cells
|
Multiple myeloma, Plasma cell myeloma
|
Undisclosed | |
| Half Maximal Growth Inhibitory Concentration (GI50) | 100 | nM |
Cancer cells
|
Multiple myeloma, Plasma cell myeloma
|
Undisclosed | |
| Half Maximal Growth Inhibitory Concentration (GI50) | 100 | nM |
Cancer cells
|
Multiple myeloma, Plasma cell myeloma
|
Undisclosed | |
| Half Maximal Growth Inhibitory Concentration (GI50) | 100 | nM |
Cancer cells
|
Multiple myeloma, Plasma cell myeloma
|
Undisclosed | |
| Half Maximal Growth Inhibitory Concentration (GI50) | 100 | nM |
Cancer cells
|
Multiple myeloma, Plasma cell myeloma
|
Undisclosed | |
| Half Maximal Growth Inhibitory Concentration (GI50) | 100 | nM |
Cancer cells
|
Multiple myeloma, Plasma cell myeloma
|
Undisclosed | |
| Half Maximal Inhibitory Concentration (IC50) | >100 | nM |
Cancer cells
|
Multiple myeloma, Plasma cell myeloma
|
Undisclosed | |
| Half Maximal Growth Inhibitory Concentration (GI50) | 100 | nM |
Cancer cells
|
Multiple myeloma, Plasma cell myeloma
|
Undisclosed | |
| Half Maximal Growth Inhibitory Concentration (GI50) | 100 | nM |
Cancer cells
|
Multiple myeloma, Plasma cell myeloma
|
Undisclosed | |
| Half Maximal Growth Inhibitory Concentration (GI50) | 100 | nM |
Leukemia cells
|
Multiple myeloma, Plasma cell myeloma
|
Undisclosed | |
| Half Maximal Growth Inhibitory Concentration (GI50) | 100 | nM |
Leukemia cells
|
Multiple myeloma, Plasma cell myeloma
|
Undisclosed | |
| Half Maximal Growth Inhibitory Concentration (GI50) | 100 | nM |
Leukemia cells
|
Multiple myeloma, Plasma cell myeloma
|
Undisclosed | |
| Half Maximal Growth Inhibitory Concentration (GI50) | 100 | nM |
Leukemia cells
|
Multiple myeloma, Plasma cell myeloma
|
Undisclosed | |
| Half Maximal Growth Inhibitory Concentration (GI50) | 100 | nM |
Leukemia cells
|
Multiple myeloma, Plasma cell myeloma
|
Undisclosed | |
| Half Maximal Growth Inhibitory Concentration (GI50) | 100 | nM |
Leukemia cells
|
Multiple myeloma, Plasma cell myeloma
|
Undisclosed | |
| Half Maximal Growth Inhibitory Concentration (GI50) | 100 | nM |
Leukemia cells
|
Multiple myeloma, Plasma cell myeloma
|
Undisclosed | |
| Half Maximal Growth Inhibitory Concentration (GI50) | 100 | nM |
Leukemia cells
|
Multiple myeloma, Plasma cell myeloma
|
Undisclosed | |
| Half Maximal Growth Inhibitory Concentration (GI50) | 100 | nM |
Leukemia cells
|
Multiple myeloma, Plasma cell myeloma
|
Undisclosed | |
| Half Maximal Inhibitory Concentration (IC50) | >100 | nM |
SNU-449 cells
|
Hepatocellular carcinoma
|
||
| Half Maximal Growth Inhibitory Concentration (GI50) | 100 | nM |
DMS-273 cells
|
Small cell lung carcinoma
|
||
| Half Maximal Growth Inhibitory Concentration (GI50) | 100 | nM |
SR cells
|
Leukemia
|
||
| Half Maximal Growth Inhibitory Concentration (GI50) | 100 | nM |
P388 cells
|
Lymphoma
|
||
| Half Maximal Growth Inhibitory Concentration (GI50) | 100 | nM |
RXF 631 cells
|
Renal carcinoma
|
||
| Half Maximal Growth Inhibitory Concentration (GI50) | 100 | nM |
LXFL 529 cells
|
Non-small cell lung carcinoma
|
||
| Half Maximal Growth Inhibitory Concentration (GI50) | 100 | nM |
SN12K1 cells
|
Lung metastasis of renal carcinoma
|
||
| Half Maximal Effective Concentration (EC50) | <100 | nM | Undisclosed | Undisclosed | Undisclosed | |
| Half Maximal Inhibitory Concentration (IC50) | 100 | nM | Undisclosed | Undisclosed | Undisclosed | |
| Half Maximal Effective Concentration (EC50) | <100 | nM | Undisclosed | Undisclosed | Undisclosed | |
| Half Maximal Inhibitory Concentration (IC50) | 100 | nM | Undisclosed | Undisclosed | Undisclosed | |
| Half Maximal Inhibitory Concentration (IC50) | 100 | nM | Undisclosed | Undisclosed | Undisclosed | |
| Half Maximal Inhibitory Concentration (IC50) | 100 | nM | Undisclosed | Undisclosed | Undisclosed | |
| Half Maximal Growth Inhibitory Concentration (GI50) | 100 | nM | Undisclosed | Undisclosed | Undisclosed | |
| Half Maximal Inhibitory Concentration (IC50) | >100 | nM | Undisclosed | Undisclosed | Undisclosed | |
| Half Maximal Inhibitory Concentration (IC50) | >100 | nM | Undisclosed | Undisclosed | Undisclosed | |
| Half Maximal Growth Inhibitory Concentration (GI50) | 100 | nM | Undisclosed | Undisclosed | Undisclosed | |
| Half Maximal Effective Concentration (EC50) | <100 | nM | Undisclosed | Undisclosed | Undisclosed | |
| Half Maximal Inhibitory Concentration (IC50) | 1000 | nM |
KB cells
|
Human papillomavirus-related endocervical adenocarcinoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 1000 | nM | Undisclosed | Undisclosed | Undisclosed | |
| Half Maximal Inhibitory Concentration (IC50) | <1000 | nM | Undisclosed | Undisclosed | Undisclosed | |
| Half Maximal Inhibitory Concentration (IC50) | 10000 | nM | Undisclosed | Undisclosed | Undisclosed | |
| Half Maximal Inhibitory Concentration (IC50) | >100000 | nM |
KB cells
|
Human papillomavirus-related endocervical adenocarcinoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 100000 | nM |
Cancer cells
|
Multiple myeloma, Plasma cell myeloma
|
Undisclosed | |
| Half Maximal Inhibitory Concentration (IC50) | >100000 | nM |
Cancer cells
|
Multiple myeloma, Plasma cell myeloma
|
Undisclosed | |
| Half Maximal Inhibitory Concentration (IC50) | 10050 | nM |
Cancer cells
|
Multiple myeloma, Plasma cell myeloma
|
Undisclosed | |
| Half Maximal Inhibitory Concentration (IC50) | 10050 | nM |
Cancer cells
|
Multiple myeloma, Plasma cell myeloma
|
Undisclosed | |
| Half Maximal Inhibitory Concentration (IC50) | 10200 | nM |
Cancer cells
|
Multiple myeloma, Plasma cell myeloma
|
Undisclosed | |
| Half Maximal Inhibitory Concentration (IC50) | 1030 | nM |
NCI-H157 cells
|
Non-small cell lung carcinoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 1030 | nM |
NCI-H157 cells
|
Non-small cell lung carcinoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 1030 | nM |
NCI-H157 cells
|
Non-small cell lung carcinoma
|
||
| Half Maximal Growth Inhibitory Concentration (GI50) | 104 | nM |
PC-12 cells
|
Adrenal phaeochromacytoma
|
||
| Half Maximal Growth Inhibitory Concentration (GI50) | 104.95 | nM |
NCI-H460 cells
|
Lung large cell carcinoma
|
||
| Half Maximal Growth Inhibitory Concentration (GI50) | 105.93 | nM |
DLD-1 cells
|
Colon adenocarcinoma
|
||
| Half Maximal Growth Inhibitory Concentration (GI50) | 106.17 | nM |
KM-20L2 cells
|
Colon carcinoma
|
||
| Half Maximal Growth Inhibitory Concentration (GI50) | 106590 | nM |
MDCK-II cells
|
Normal
|
||
| Half Maximal Inhibitory Concentration (IC50) | 1080 | nM |
Cancer cells
|
Multiple myeloma, Plasma cell myeloma
|
Undisclosed | |
| Half Maximal Inhibitory Concentration (IC50) | 11 | nM |
PC-3 cells
|
Prostate carcinoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 11000 | nM |
HEK293 cells
|
Normal
|
||
| Half Maximal Activity Concentration (AC50) | 11157.6 | nM | Undisclosed | Undisclosed | Undisclosed | |
| Half Maximal Growth Inhibitory Concentration (GI50) | 112.46 | nM |
NCI-H23 cells
|
Lung adenocarcinoma
|
||
| Half Maximal Growth Inhibitory Concentration (GI50) | 112.72 | nM |
K562 cells
|
Blast phase chronic myelogenous leukemia, BCR-ABL1 positive, Chronic myeloid leukemia
|
||
| Half Maximal Growth Inhibitory Concentration (GI50) | 112.98 | nM |
IGROV-1 cells
|
Endometrioid carcinoma of ovary, Ovarian endometrioid adenocarcinoma
|
||
| Half Maximal Growth Inhibitory Concentration (GI50) | 114.82 | nM |
MOLT-4 cells
|
Adult T acute lymphoblastic leukemia
|
||
| Half Maximal Inhibitory Concentration (IC50) | 116.6 | nM |
MDA-MB-231 cells
|
Breast adenocarcinoma
|
||
| Half Maximal Growth Inhibitory Concentration (GI50) | 117.22 | nM |
NCI-H322M cells
|
Minimally invasive lung adenocarcinoma
|
||
| Half Maximal Growth Inhibitory Concentration (GI50) | 117.22 | nM |
OVCAR-8 cells
|
High grade ovarian serous adenocarcinoma
|
||
| Half Maximal Growth Inhibitory Concentration (GI50) | 117.49 | nM |
SW620 cells
|
Colon adenocarcinoma
|
||
| Half Maximal Growth Inhibitory Concentration (GI50) | 118.3 | nM |
SF539 cells
|
Gliosarcoma
|
||
| Half Maximal Growth Inhibitory Concentration (GI50) | 118.3 | nM |
LOX IMVI cells
|
Melanoma
|
||
| Half Maximal Growth Inhibitory Concentration (GI50) | 118.85 | nM |
HT-29 cells
|
Colon adenocarcinoma
|
||
| Half Maximal Growth Inhibitory Concentration (GI50) | 119.12 | nM |
NCI-H522 cells
|
Non-small cell lung carcinoma
|
||
| Half Maximal Growth Inhibitory Concentration (GI50) | 119.67 | nM |
MCF-7 cells
|
Invasive breast carcinoma of no special type
|
||
| Half Maximal Inhibitory Concentration (IC50) | 12 | nM |
HT-29 cells
|
Colon adenocarcinoma
|
||
| Half Maximal Effective Concentration (EC50) | 12 | nM |
SNU-398 cells
|
Hepatocellular carcinoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 12 | nM |
MX1 cells
|
Breast carcinoma
|
||
| Median Effective Dose (ED50) | 12.1 | nM |
MCF-7 cells
|
Invasive breast carcinoma of no special type
|
||
| Median Effective Dose (ED50) | 12.1 | nM |
PC-3 cells
|
Prostate carcinoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 12.7 | nM |
PLC-PRF-5 cells
|
Hepatocellular carcinoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | <120 | nM |
AGS cells
|
Gastric adenocarcinoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | <120 | nM |
SMMC-7721 cells
|
Hepatocellular carcinoma
|
||
| Half Maximal Activity Concentration (AC50) | 120 | nM | Undisclosed | Undisclosed | Undisclosed | |
| Half Maximal Growth Inhibitory Concentration (GI50) | 120.5 | nM |
A549 cells
|
Lung adenocarcinoma
|
||
| Half Maximal Growth Inhibitory Concentration (GI50) | 120.5 | nM |
HL-60 cells
|
Acute myeloblastic leukemia with maturation, Adult acute myeloid leukemia with maturation
|
||
| Half Maximal Growth Inhibitory Concentration (GI50) | 120.5 | nM |
RPMI-8226 cells
|
Plasma cell myeloma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 1200 | nM |
Cancer cells
|
Multiple myeloma, Plasma cell myeloma
|
Undisclosed | |
| Half Maximal Inhibitory Concentration (IC50) | 1200 | nM |
Cancer cells
|
Multiple myeloma, Plasma cell myeloma
|
Undisclosed | |
| Half Maximal Growth Inhibitory Concentration (GI50) | 1200 | nM |
Cancer cells
|
Multiple myeloma, Plasma cell myeloma
|
Undisclosed | |
| Half Maximal Growth Inhibitory Concentration (GI50) | 121.06 | nM |
DMS 114 cells
|
Lung small cell carcinoma
|
||
| Half Maximal Growth Inhibitory Concentration (GI50) | 121.34 | nM |
KM12 cells
|
Colon adenocarcinoma
|
||
| Half Maximal Growth Inhibitory Concentration (GI50) | 121.9 | nM |
HCC 2998 cells
|
Colon adenocarcinoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 1230.48 | nM |
KB 3-1 cells
|
Cervical epithelial carcinoma
|
||
| Half Maximal Growth Inhibitory Concentration (GI50) | 124.45 | nM |
SK-MEL-5 cells
|
Cutaneous melanoma
|
||
| Half Maximal Growth Inhibitory Concentration (GI50) | 124.45 | nM |
SF-295 cells
|
Glioblastoma
|
||
| Half Maximal Growth Inhibitory Concentration (GI50) | 125.03 | nM |
OVCAR-3 cells
|
High grade ovarian serous adenocarcinoma
|
||
| Half Maximal Growth Inhibitory Concentration (GI50) | 125.6 | nM |
A498 cells
|
Renal carcinoma
|
||
| Half Maximal Growth Inhibitory Concentration (GI50) | 125.89 | nM |
Cancer cells
|
Multiple myeloma, Plasma cell myeloma
|
Undisclosed | |
| Half Maximal Growth Inhibitory Concentration (GI50) | 125.89 | nM |
Cancer cells
|
Multiple myeloma, Plasma cell myeloma
|
Undisclosed | |
| Half Maximal Growth Inhibitory Concentration (GI50) | 125.89 | nM |
Cancer cells
|
Multiple myeloma, Plasma cell myeloma
|
Undisclosed | |
| Half Maximal Growth Inhibitory Concentration (GI50) | 125.89 | nM |
Cancer cells
|
Multiple myeloma, Plasma cell myeloma
|
Undisclosed | |
| Half Maximal Growth Inhibitory Concentration (GI50) | 125.89 | nM |
Cancer cells
|
Multiple myeloma, Plasma cell myeloma
|
Undisclosed | |
| Half Maximal Growth Inhibitory Concentration (GI50) | 125.89 | nM |
Cancer cells
|
Multiple myeloma, Plasma cell myeloma
|
Undisclosed | |
| Half Maximal Growth Inhibitory Concentration (GI50) | 125.89 | nM |
Cancer cells
|
Multiple myeloma, Plasma cell myeloma
|
Undisclosed | |
| Half Maximal Growth Inhibitory Concentration (GI50) | 125.89 | nM |
Cancer cells
|
Multiple myeloma, Plasma cell myeloma
|
Undisclosed | |
| Half Maximal Growth Inhibitory Concentration (GI50) | 125.89 | nM |
Cancer cells
|
Multiple myeloma, Plasma cell myeloma
|
Undisclosed | |
| Half Maximal Growth Inhibitory Concentration (GI50) | 125.89 | nM | Undisclosed | Undisclosed | Undisclosed | |
| Half Maximal Inhibitory Concentration (IC50) | 1261 | nM |
Cancer cells
|
Multiple myeloma, Plasma cell myeloma
|
Undisclosed | |
| Half Maximal Inhibitory Concentration (IC50) | 1290 | nM |
KB cells
|
Human papillomavirus-related endocervical adenocarcinoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 13 | nM |
MCF-7 cells
|
Invasive breast carcinoma of no special type
|
||
| Half Maximal Inhibitory Concentration (IC50) | 13.71 | nM |
Cancer cells
|
Multiple myeloma, Plasma cell myeloma
|
Undisclosed | |
| Half Maximal Growth Inhibitory Concentration (GI50) | 130 | nM |
Cancer cells
|
Multiple myeloma, Plasma cell myeloma
|
Undisclosed | |
| Half Maximal Growth Inhibitory Concentration (GI50) | 130 | nM |
Cancer cells
|
Multiple myeloma, Plasma cell myeloma
|
Undisclosed | |
| Half Maximal Growth Inhibitory Concentration (GI50) | 130 | nM |
Cancer cells
|
Multiple myeloma, Plasma cell myeloma
|
Undisclosed | |
| Half Maximal Growth Inhibitory Concentration (GI50) | 130 | nM |
Cancer cells
|
Multiple myeloma, Plasma cell myeloma
|
Undisclosed | |
| Half Maximal Growth Inhibitory Concentration (GI50) | 130 | nM |
Cancer cells
|
Multiple myeloma, Plasma cell myeloma
|
Undisclosed | |
| Half Maximal Growth Inhibitory Concentration (GI50) | 130 | nM |
Cancer cells
|
Multiple myeloma, Plasma cell myeloma
|
Undisclosed | |
| Half Maximal Growth Inhibitory Concentration (GI50) | 130 | nM |
Cancer cells
|
Multiple myeloma, Plasma cell myeloma
|
Undisclosed | |
| Half Maximal Growth Inhibitory Concentration (GI50) | 130.62 | nM |
CCRF-CEM cells
|
T acute lymphoblastic leukemia
|
||
| Half Maximal Growth Inhibitory Concentration (GI50) | 130.62 | nM |
SNB-19 cells
|
Astrocytoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 1300 | nM |
MCF-7 cells
|
Invasive breast carcinoma of no special type
|
||
| Half Maximal Growth Inhibitory Concentration (GI50) | 1306.17 | nM |
SK-MEL-28 cells
|
Cutaneous melanoma
|
||
| Half Maximal Growth Inhibitory Concentration (GI50) | 131.83 | nM |
U251 cells
|
Astrocytoma
|
||
| Half Maximal Growth Inhibitory Concentration (GI50) | 132.43 | nM |
HCT116 cells
|
Colon carcinoma
|
||
| Half Maximal Growth Inhibitory Concentration (GI50) | 132.43 | nM |
SK-MEL-2 cells
|
Melanoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 1320 | nM | Undisclosed | Undisclosed | Undisclosed | |
| Half Maximal Growth Inhibitory Concentration (GI50) | 133.05 | nM |
SN12C cells
|
Renal cell carcinoma
|
||
| Half Maximal Growth Inhibitory Concentration (GI50) | 133.05 | nM |
COLO 205 cells
|
Colon adenocarcinoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | >133000 | nM | Undisclosed | Undisclosed | Undisclosed | |
| Half Maximal Inhibitory Concentration (IC50) | >133000 | nM | Undisclosed | Undisclosed | Undisclosed | |
| Half Maximal Inhibitory Concentration (IC50) | >133000 | nM | Undisclosed | Undisclosed | Undisclosed | |
| Half Maximal Inhibitory Concentration (IC50) | >133000 | nM | Undisclosed | Undisclosed | Undisclosed | |
| Half Maximal Inhibitory Concentration (IC50) | 1335 | nM |
Cancer cells
|
Multiple myeloma, Plasma cell myeloma
|
Undisclosed | |
| Half Maximal Growth Inhibitory Concentration (GI50) | 134.9 | nM |
XF498 cells
|
Glioma
|
||
| Half Maximal Growth Inhibitory Concentration (GI50) | 136.77 | nM |
HOP-92 cells
|
Non-small cell lung carcinoma
|
||
| Half Maximal Growth Inhibitory Concentration (GI50) | 137.09 | nM |
HCT-15 cells
|
Colon adenocarcinoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 139 | nM |
KB cells
|
Human papillomavirus-related endocervical adenocarcinoma
|
||
| Half Maximal Growth Inhibitory Concentration (GI50) | 139.64 | nM |
CAKI-1 cells
|
Clear cell renal cell carcinoma
|
||
| Half Maximal Growth Inhibitory Concentration (GI50) | 140.28 | nM |
M14 cells
|
Melanoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 141 | nM |
HeLa cells
|
Human papillomavirus-related endocervical adenocarcinoma
|
||
| Half Maximal Growth Inhibitory Concentration (GI50) | 141.58 | nM |
M19-MEL cells
|
Melanoma
|
||
| Half Maximal Growth Inhibitory Concentration (GI50) | 145.21 | nM |
UACC-62 cells
|
Melanoma
|
||
| Half Maximal Growth Inhibitory Concentration (GI50) | 147.91 | nM |
786-O cells
|
Renal cell carcinoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 1483.48 | nM |
Cancer cells
|
Multiple myeloma, Plasma cell myeloma
|
Undisclosed | |
| Half Maximal Inhibitory Concentration (IC50) | 1489.58 | nM |
Cancer cells
|
Multiple myeloma, Plasma cell myeloma
|
Undisclosed | |
| Half Maximal Growth Inhibitory Concentration (GI50) | 149.97 | nM |
NCI-H226 cells
|
Pleural epithelioid mesothelioma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 15 | nM |
MDA-MB-231 cells
|
Breast adenocarcinoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 15 | nM |
PC-3 cells
|
Prostate carcinoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 15 | nM |
HeLa cells
|
Human papillomavirus-related endocervical adenocarcinoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 15 | nM |
HeLa cells
|
Human papillomavirus-related endocervical adenocarcinoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 15 | nM |
MIA PaCa-2 cells
|
Pancreatic undifferentiated carcinoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 15.3 | nM |
PC-3 cells
|
Prostate carcinoma
|
||
| Half Maximal Activity Concentration (AC50) | 153.4 | nM | Undisclosed | Undisclosed | Undisclosed | |
| Half Maximal Activity Concentration (AC50) | 153.4 | nM | Undisclosed | Undisclosed | Undisclosed | |
| Half Maximal Growth Inhibitory Concentration (GI50) | 158.49 | nM |
Melanoma cells
|
Multiple myeloma, Plasma cell myeloma
|
Undisclosed | |
| Half Maximal Growth Inhibitory Concentration (GI50) | 158.49 | nM |
Melanoma cells
|
Multiple myeloma, Plasma cell myeloma
|
Undisclosed | |
| Half Maximal Growth Inhibitory Concentration (GI50) | 158.49 | nM |
Melanoma cells
|
Multiple myeloma, Plasma cell myeloma
|
Undisclosed | |
| Half Maximal Growth Inhibitory Concentration (GI50) | 158.49 | nM |
Cancer cells
|
Multiple myeloma, Plasma cell myeloma
|
Undisclosed | |
| Half Maximal Growth Inhibitory Concentration (GI50) | 158.49 | nM |
Cancer cells
|
Multiple myeloma, Plasma cell myeloma
|
Undisclosed | |
| Tumor Growth Inhibition (TGI) | 15800 | nM |
Leukemia cells
|
Multiple myeloma, Plasma cell myeloma
|
Undisclosed | |
| Tumor Growth Inhibition (TGI) | 15800 | nM |
Leukemia cells
|
Multiple myeloma, Plasma cell myeloma
|
Undisclosed | |
| Tumor Growth Inhibition (TGI) | 15800 | nM |
NSCLC cells
|
Multiple myeloma, Plasma cell myeloma
|
Undisclosed | |
| Tumor Growth Inhibition (TGI) | 15800 | nM |
NSCLC cells
|
Multiple myeloma, Plasma cell myeloma
|
Undisclosed | |
| Half Maximal Inhibitory Concentration (IC50) | 1584.89 | nM | Undisclosed | Undisclosed | Undisclosed | |
| Tumor Growth Inhibition (TGI) | 15848.93 | nM |
Cancer cells
|
Multiple myeloma, Plasma cell myeloma
|
Undisclosed | |
| Tumor Growth Inhibition (TGI) | 15848.93 | nM |
Leukemia cells
|
Multiple myeloma, Plasma cell myeloma
|
Undisclosed | |
| Tumor Growth Inhibition (TGI) | 15848.93 | nM |
Leukemia cells
|
Multiple myeloma, Plasma cell myeloma
|
Undisclosed | |
| Tumor Growth Inhibition (TGI) | 15848.93 | nM |
Leukemia cells
|
Multiple myeloma, Plasma cell myeloma
|
Undisclosed | |
| Tumor Growth Inhibition (TGI) | 15848.93 | nM |
NSCLC cells
|
Multiple myeloma, Plasma cell myeloma
|
Undisclosed | |
| Tumor Growth Inhibition (TGI) | 15848.93 | nM |
NSCLC cells
|
Multiple myeloma, Plasma cell myeloma
|
Undisclosed | |
| Tumor Growth Inhibition (TGI) | 15848.93 | nM |
NSCLC cells
|
Multiple myeloma, Plasma cell myeloma
|
Undisclosed | |
| Tumor Growth Inhibition (TGI) | 15848.93 | nM | Undisclosed | Undisclosed | Undisclosed | |
| Tumor Growth Inhibition (TGI) | 15850 | nM |
Leukemia cells
|
Multiple myeloma, Plasma cell myeloma
|
Undisclosed | |
| Tumor Growth Inhibition (TGI) | 15850 | nM |
Leukemia cells
|
Multiple myeloma, Plasma cell myeloma
|
Undisclosed | |
| Tumor Growth Inhibition (TGI) | 15850 | nM |
Leukemia cells
|
Multiple myeloma, Plasma cell myeloma
|
Undisclosed | |
| Tumor Growth Inhibition (TGI) | 15850 | nM |
NSCLC cells
|
Multiple myeloma, Plasma cell myeloma
|
Undisclosed | |
| Tumor Growth Inhibition (TGI) | 15850 | nM |
NSCLC cells
|
Multiple myeloma, Plasma cell myeloma
|
Undisclosed | |
| Tumor Growth Inhibition (TGI) | 15850 | nM |
NSCLC cells
|
Multiple myeloma, Plasma cell myeloma
|
Undisclosed | |
| Half Maximal Inhibitory Concentration (IC50) | 16.7 | nM |
KB cells
|
Human papillomavirus-related endocervical adenocarcinoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 16.9 | nM |
Cancer cells
|
Multiple myeloma, Plasma cell myeloma
|
Undisclosed | |
| Half Maximal Growth Inhibitory Concentration (GI50) | 160 | nM |
Melanoma cells
|
Multiple myeloma, Plasma cell myeloma
|
Undisclosed | |
| Half Maximal Growth Inhibitory Concentration (GI50) | 160 | nM |
Melanoma cells
|
Multiple myeloma, Plasma cell myeloma
|
Undisclosed | |
| Half Maximal Growth Inhibitory Concentration (GI50) | 160 | nM |
Melanoma cells
|
Multiple myeloma, Plasma cell myeloma
|
Undisclosed | |
| Half Maximal Growth Inhibitory Concentration (GI50) | 161.06 | nM |
RXF 393 cells
|
Renal carcinoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 1610 | nM |
KB cells
|
Human papillomavirus-related endocervical adenocarcinoma
|
||
| Half Maximal Growth Inhibitory Concentration (GI50) | 162.18 | nM |
UACC-257 cells
|
Melanoma
|
||
| Half Maximal Growth Inhibitory Concentration (GI50) | 162.93 | nM |
SNB-78 cells
|
Glioblastoma
|
||
| Half Maximal Growth Inhibitory Concentration (GI50) | 164.06 | nM |
MDA-MB-435 cells
|
Amelanotic melanoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 168 | nM |
Cancer cells
|
Multiple myeloma, Plasma cell myeloma
|
Undisclosed | |
| Half Maximal Inhibitory Concentration (IC50) | 17 | nM |
HT-29 cells
|
Colon adenocarcinoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 17 | nM |
Cancer cells
|
Multiple myeloma, Plasma cell myeloma
|
Undisclosed | |
| Half Maximal Inhibitory Concentration (IC50) | 17.29 | nM |
K562 cells
|
Blast phase chronic myelogenous leukemia, BCR-ABL1 positive, Chronic myeloid leukemia
|
||
| Half Maximal Inhibitory Concentration (IC50) | 17.6 | nM |
KB cells
|
Human papillomavirus-related endocervical adenocarcinoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 17.6 | nM |
Cancer cells
|
Multiple myeloma, Plasma cell myeloma
|
Undisclosed | |
| Half Maximal Inhibitory Concentration (IC50) | 17.6 | nM |
Cancer cells
|
Multiple myeloma, Plasma cell myeloma
|
Undisclosed | |
| Half Maximal Inhibitory Concentration (IC50) | 17.6 | nM |
Cancer cells
|
Multiple myeloma, Plasma cell myeloma
|
Undisclosed | |
| Half Maximal Inhibitory Concentration (IC50) | 170 | nM |
A2780 cells
|
Ovarian endometrioid adenocarcinoma
|
||
| Half Maximal Growth Inhibitory Concentration (GI50) | 171.4 | nM |
P388/ADR cells
|
Lymphoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 171.5 | nM |
A549 cells
|
Lung adenocarcinoma
|
||
| Half Maximal Growth Inhibitory Concentration (GI50) | 171.79 | nM |
SF268 cells
|
Astrocytoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 173 | nM |
HCT-8 cells
|
Ileocecal adenocarcinoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 1740 | nM |
HT-29 cells
|
Colon adenocarcinoma
|
||
| Half Maximal Growth Inhibitory Concentration (GI50) | 174984.67 | nM |
T47D cells
|
Invasive breast carcinoma of no special type
|
||
| Half Maximal Growth Inhibitory Concentration (GI50) | 175.79 | nM |
ACHN cells
|
Renal adenocarcinoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 178 | nM |
K562 cells
|
Blast phase chronic myelogenous leukemia, BCR-ABL1 positive, Chronic myeloid leukemia
|
||
| Half Maximal Inhibitory Concentration (IC50) | 178 | nM |
K562 cells
|
Blast phase chronic myelogenous leukemia, BCR-ABL1 positive, Chronic myeloid leukemia
|
||
| Half Maximal Inhibitory Concentration (IC50) | 18 | nM |
A549 cells
|
Lung adenocarcinoma
|
||
| Half Maximal Growth Inhibitory Concentration (GI50) | 18 | nM |
MCF-7 cells
|
Invasive breast carcinoma of no special type
|
||
| Half Maximal Growth Inhibitory Concentration (GI50) | 18 | nM |
PC-3 cells
|
Prostate carcinoma
|
||
| Half Maximal Growth Inhibitory Concentration (GI50) | 18 | nM |
DU145 cells
|
Prostate carcinoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 18.4 | nM |
SNU-423 cells
|
Hepatocellular carcinoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 1800 | nM |
HL-60 cells
|
Acute myeloblastic leukemia with maturation, Adult acute myeloid leukemia with maturation
|
||
| Half Maximal Inhibitory Concentration (IC50) | 1800 | nM | Undisclosed | Undisclosed | Undisclosed | |
| Half Maximal Inhibitory Concentration (IC50) | 1875750 | nM |
Cancer cells
|
Multiple myeloma, Plasma cell myeloma
|
Undisclosed | |
| Half Maximal Inhibitory Concentration (IC50) | 190 | nM |
P388 cells
|
Lymphoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 1900 | nM |
HCT-8 cells
|
Ileocecal adenocarcinoma
|
||
| Half Maximal Growth Inhibitory Concentration (GI50) | 199.53 | nM |
NCI cells
|
Multiple myeloma, Plasma cell myeloma
|
Undisclosed | |
| Half Maximal Inhibitory Concentration (IC50) | 199.53 | nM | Undisclosed | Undisclosed | Undisclosed | |
| Tumor Growth Inhibition (TGI) | 19900 | nM |
Cancer cells
|
Multiple myeloma, Plasma cell myeloma
|
Undisclosed | |
| Tumor Growth Inhibition (TGI) | 19900 | nM |
Cancer cells
|
Multiple myeloma, Plasma cell myeloma
|
Undisclosed | |
| Tumor Growth Inhibition (TGI) | 19900 | nM |
Cancer cells
|
Multiple myeloma, Plasma cell myeloma
|
Undisclosed | |
| Tumor Growth Inhibition (TGI) | 19900 | nM |
Cancer cells
|
Multiple myeloma, Plasma cell myeloma
|
Undisclosed | |
| Tumor Growth Inhibition (TGI) | 19950 | nM |
Cancer cells
|
Multiple myeloma, Plasma cell myeloma
|
Undisclosed | |
| Tumor Growth Inhibition (TGI) | 19950 | nM |
Cancer cells
|
Multiple myeloma, Plasma cell myeloma
|
Undisclosed | |
| Tumor Growth Inhibition (TGI) | 19950 | nM |
Cancer cells
|
Multiple myeloma, Plasma cell myeloma
|
Undisclosed | |
| Tumor Growth Inhibition (TGI) | 19950 | nM |
Cancer cells
|
Multiple myeloma, Plasma cell myeloma
|
Undisclosed | |
| Tumor Growth Inhibition (TGI) | 19950 | nM |
Cancer cells
|
Multiple myeloma, Plasma cell myeloma
|
Undisclosed | |
| Tumor Growth Inhibition (TGI) | 19950 | nM |
Cancer cells
|
Multiple myeloma, Plasma cell myeloma
|
Undisclosed | |
| Tumor Growth Inhibition (TGI) | 19952.62 | nM |
Cancer cells
|
Multiple myeloma, Plasma cell myeloma
|
Undisclosed | |
| Tumor Growth Inhibition (TGI) | 19952.62 | nM |
Cancer cells
|
Multiple myeloma, Plasma cell myeloma
|
Undisclosed | |
| Tumor Growth Inhibition (TGI) | 19952.62 | nM |
Cancer cells
|
Multiple myeloma, Plasma cell myeloma
|
Undisclosed | |
| Tumor Growth Inhibition (TGI) | 19952.62 | nM |
Cancer cells
|
Multiple myeloma, Plasma cell myeloma
|
Undisclosed | |
| Tumor Growth Inhibition (TGI) | 19952.62 | nM |
Cancer cells
|
Multiple myeloma, Plasma cell myeloma
|
Undisclosed | |
| Tumor Growth Inhibition (TGI) | 19952.62 | nM |
Cancer cells
|
Multiple myeloma, Plasma cell myeloma
|
Undisclosed | |
| Half Maximal Inhibitory Concentration (IC50) | >19952.62 | nM |
Vero C1008 cells
|
Normal
|
||
| Tumor Growth Inhibition (TGI) | 19952.62 | nM | Undisclosed | Undisclosed | Undisclosed | |
| Tumor Growth Inhibition (TGI) | 19952.62 | nM | Undisclosed | Undisclosed | Undisclosed | |
| Half Maximal Inhibitory Concentration (IC50) | 2 | nM |
MCF-7 cells
|
Invasive breast carcinoma of no special type
|
||
| Half Maximal Inhibitory Concentration (IC50) | 2 | nM |
MCF-7 cells
|
Invasive breast carcinoma of no special type
|
||
| Half Maximal Growth Inhibitory Concentration (GI50) | 2 | nM |
KB cells
|
Human papillomavirus-related endocervical adenocarcinoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 2 | nM |
Cancer cells
|
Multiple myeloma, Plasma cell myeloma
|
Undisclosed | |
| Half Maximal Inhibitory Concentration (IC50) | 2 | nM |
P388 cells
|
Lymphoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 2.06 | nM |
HT-29 cells
|
Colon adenocarcinoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 2.1 | nM |
Cancer cells
|
Multiple myeloma, Plasma cell myeloma
|
Undisclosed | |
| Half Maximal Inhibitory Concentration (IC50) | 2.1 | nM |
Cancer cells
|
Multiple myeloma, Plasma cell myeloma
|
Undisclosed | |
| Half Maximal Inhibitory Concentration (IC50) | 2.11 | nM |
KB cells
|
Human papillomavirus-related endocervical adenocarcinoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 2.13 | nM |
CCRF-CEM cells
|
T acute lymphoblastic leukemia
|
||
| Half Maximal Inhibitory Concentration (IC50) | 2.2 | nM |
KB cells
|
Human papillomavirus-related endocervical adenocarcinoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 2.2 | nM |
KB cells
|
Human papillomavirus-related endocervical adenocarcinoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 2.2 | nM |
KB cells
|
Human papillomavirus-related endocervical adenocarcinoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 2.2 | nM |
P388 cells
|
Lymphoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 2.32 | nM |
CCRF-CEM cells
|
T acute lymphoblastic leukemia
|
||
| Half Maximal Effective Concentration (EC50) | 2.4 | nM |
KB cells
|
Human papillomavirus-related endocervical adenocarcinoma
|
||
| Median Effective Dose (ED50) | 2.4 | nM |
KB cells
|
Human papillomavirus-related endocervical adenocarcinoma
|
||
| Half Maximal Effective Concentration (EC50) | 2.4 | nM |
KB cells
|
Human papillomavirus-related endocervical adenocarcinoma
|
||
| Half Maximal Effective Concentration (EC50) | 2.4 | nM |
KB cells
|
Human papillomavirus-related endocervical adenocarcinoma
|
||
| Half Maximal Effective Concentration (EC50) | 2.4 | nM |
KB cells
|
Human papillomavirus-related endocervical adenocarcinoma
|
||
| Half Maximal Effective Concentration (EC50) | 2.4 | nM |
KB cells
|
Human papillomavirus-related endocervical adenocarcinoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 2.4 | nM | Undisclosed | Undisclosed | Undisclosed | |
| Half Maximal Inhibitory Concentration (IC50) | 2.6 | nM |
COLO 205 cells
|
Colon adenocarcinoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 2.6 | nM |
COLO 205 cells
|
Colon adenocarcinoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 2.6 | nM |
COLO 205 cells
|
Colon adenocarcinoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 2.8 | nM |
KB cells
|
Human papillomavirus-related endocervical adenocarcinoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 2.8 | nM |
Cancer cells
|
Multiple myeloma, Plasma cell myeloma
|
Undisclosed | |
| Median Effective Dose (ED50) | 2.9 | nM |
HepG2 cells
|
Hepatoblastoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 2.9 | nM |
BT-474 cells
|
Invasive breast carcinoma of no special type
|
||
| Half Maximal Inhibitory Concentration (IC50) | 2.9 | nM |
LNCaP cells
|
Prostate carcinoma
|
||
| Half Maximal Growth Inhibitory Concentration (GI50) | 2.9 | nM |
Cancer cells
|
Multiple myeloma, Plasma cell myeloma
|
Undisclosed | |
| Half Maximal Growth Inhibitory Concentration (GI50) | 20 | nM |
A549 cells
|
Lung adenocarcinoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 20 | nM |
A549 cells
|
Lung adenocarcinoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 20 | nM |
MCF-7 cells
|
Invasive breast carcinoma of no special type
|
||
| Half Maximal Inhibitory Concentration (IC50) | 20 | nM |
MCF-7 cells
|
Invasive breast carcinoma of no special type
|
||
| Half Maximal Inhibitory Concentration (IC50) | 20 | nM |
MDA-MB-231 cells
|
Breast adenocarcinoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 20 | nM |
Huh-7 cells
|
Adult hepatocellular carcinoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 20 | nM |
KB cells
|
Human papillomavirus-related endocervical adenocarcinoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 20 | nM |
KB cells
|
Human papillomavirus-related endocervical adenocarcinoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 20 | nM |
MDA-MB-435 cells
|
Amelanotic melanoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 20 | nM |
OVCAR-3 cells
|
High grade ovarian serous adenocarcinoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 20 | nM |
OVCAR-3 cells
|
High grade ovarian serous adenocarcinoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 20 | nM |
Cancer cells
|
Multiple myeloma, Plasma cell myeloma
|
Undisclosed | |
| Half Maximal Inhibitory Concentration (IC50) | 20 | nM |
4T1 cells
|
Malignant neoplasms of the mouse mammary gland
|
||
| Half Maximal Effective Concentration (EC50) | 20 | nM |
P388 cells
|
Lymphoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 200 | nM |
HepG2 cells
|
Hepatoblastoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 200 | nM |
HepG2 cells
|
Hepatoblastoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 200 | nM |
KB cells
|
Human papillomavirus-related endocervical adenocarcinoma
|
||
| Half Maximal Growth Inhibitory Concentration (GI50) | 200 | nM |
Melanoma cells
|
Multiple myeloma, Plasma cell myeloma
|
Undisclosed | |
| Half Maximal Growth Inhibitory Concentration (GI50) | 200 | nM |
Melanoma cells
|
Multiple myeloma, Plasma cell myeloma
|
Undisclosed | |
| Half Maximal Growth Inhibitory Concentration (GI50) | 200 | nM |
Cancer cells
|
Multiple myeloma, Plasma cell myeloma
|
Undisclosed | |
| Half Maximal Growth Inhibitory Concentration (GI50) | 200 | nM |
NSCLC cells
|
Multiple myeloma, Plasma cell myeloma
|
Undisclosed | |
| Half Maximal Growth Inhibitory Concentration (GI50) | 200 | nM |
NSCLC cells
|
Multiple myeloma, Plasma cell myeloma
|
Undisclosed | |
| Half Maximal Inhibitory Concentration (IC50) | 200 | nM |
L02 cells
|
Human papillomavirus-related endocervical adenocarcinoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 200 | nM | Undisclosed | Undisclosed | Undisclosed | |
| Half Maximal Inhibitory Concentration (IC50) | >20000 | nM |
Vero C1008 cells
|
Normal
|
||
| Half Maximal Inhibitory Concentration (IC50) | 2013 | nM |
Cancer cells
|
Multiple myeloma, Plasma cell myeloma
|
Undisclosed | |
| Half Maximal Inhibitory Concentration (IC50) | 2035 | nM |
KB-V1 cells
|
Cervical carcinoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 2035 | nM |
KB-V1 cells
|
Cervical carcinoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 2035 | nM |
KB-V1 cells
|
Cervical carcinoma
|
||
| Half Maximal Growth Inhibitory Concentration (GI50) | 20844.91 | nM |
HOP-18 cells
|
Non-small cell lung adenocarcinoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 21 | nM |
K562 cells
|
Blast phase chronic myelogenous leukemia, BCR-ABL1 positive, Chronic myeloid leukemia
|
||
| Half Maximal Inhibitory Concentration (IC50) | 21.2 | nM |
MHCC97H cells
|
Hepatocellular carcinoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 210 | nM |
HepG2 cells
|
Hepatoblastoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 210 | nM |
HT-29 cells
|
Colon adenocarcinoma
|
||
| Half Maximal Growth Inhibitory Concentration (GI50) | 210.38 | nM |
MDA-MB-231 cells
|
Breast adenocarcinoma
|
||
| Half Maximal Growth Inhibitory Concentration (GI50) | 210.38 | nM |
PC-3 cells
|
Prostate carcinoma
|
||
| Half Maximal Growth Inhibitory Concentration (GI50) | 210.38 | nM |
MDA-N cells
|
Breast carcinoma
|
||
| Half Maximal Growth Inhibitory Concentration (GI50) | 21000 | nM |
Cancer cells
|
Multiple myeloma, Plasma cell myeloma
|
Undisclosed | |
| Half Maximal Growth Inhibitory Concentration (GI50) | 2103.78 | nM |
UO-31 cells
|
Renal carcinoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 2128 | nM |
CCRF-CEM cells
|
T acute lymphoblastic leukemia
|
||
| Half Maximal Activity Concentration (AC50) | 216.7 | nM | Undisclosed | Undisclosed | Undisclosed | |
| Half Maximal Inhibitory Concentration (IC50) | 217 | nM |
HCT-8 cells
|
Ileocecal adenocarcinoma
|
||
| Half Maximal Growth Inhibitory Concentration (GI50) | 219 | nM |
Cancer cells
|
Multiple myeloma, Plasma cell myeloma
|
Undisclosed | |
| Half Maximal Inhibitory Concentration (IC50) | 22.1 | nM |
PLC-PRF-5 cells
|
Hepatocellular carcinoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 220 | nM | Undisclosed | Undisclosed | Undisclosed | |
| Half Maximal Growth Inhibitory Concentration (GI50) | 22233.1 | nM |
OVCAR-5 cells
|
Ovarian serous adenocarcinoma
|
||
| Half Maximal Growth Inhibitory Concentration (GI50) | 224.91 | nM |
HOP-62 cells
|
Non-small cell lung carcinoma
|
||
| Half Maximal Growth Inhibitory Concentration (GI50) | 233.88 | nM |
Hs578T cells
|
Invasive breast carcinoma of no special type
|
||
| Half Maximal Growth Inhibitory Concentration (GI50) | 2355.05 | nM |
EKVX cells
|
Non-small cell lung carcinoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 238.7 | nM |
Cancer cells
|
Multiple myeloma, Plasma cell myeloma
|
Undisclosed | |
| Median Effective Dose (ED50) | 24.2 | nM |
HCT-8 cells
|
Ileocecal adenocarcinoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 25.8 | nM |
HEK293 cells
|
Normal
|
||
| Half Maximal Growth Inhibitory Concentration (GI50) | 250 | nM |
NSCLC cells
|
Multiple myeloma, Plasma cell myeloma
|
Undisclosed | |
| Half Maximal Growth Inhibitory Concentration (GI50) | 250 | nM |
NSCLC cells
|
Multiple myeloma, Plasma cell myeloma
|
Undisclosed | |
| Half Maximal Growth Inhibitory Concentration (GI50) | 250 | nM |
NSCLC cells
|
Multiple myeloma, Plasma cell myeloma
|
Undisclosed | |
| Half Maximal Inhibitory Concentration (IC50) | 2500 | nM |
A549 cells
|
Lung adenocarcinoma
|
||
| Half Maximal Effective Concentration (EC50) | 2500 | nM | Undisclosed | Undisclosed | Undisclosed | |
| Half Maximal Inhibitory Concentration (IC50) | >25000 | nM |
PC-3 cells
|
Prostate carcinoma
|
||
| Half Maximal Growth Inhibitory Concentration (GI50) | 251.19 | nM |
NSCLC cells
|
Multiple myeloma, Plasma cell myeloma
|
Undisclosed | |
| Half Maximal Growth Inhibitory Concentration (GI50) | 251.19 | nM |
NSCLC cells
|
Multiple myeloma, Plasma cell myeloma
|
Undisclosed | |
| Half Maximal Growth Inhibitory Concentration (GI50) | 251.19 | nM |
NSCLC cells
|
Multiple myeloma, Plasma cell myeloma
|
Undisclosed | |
| Half Maximal Growth Inhibitory Concentration (GI50) | 251.19 | nM |
NSCLC cells
|
Multiple myeloma, Plasma cell myeloma
|
Undisclosed | |
| Half Maximal Growth Inhibitory Concentration (GI50) | 251.19 | nM | Undisclosed | Undisclosed | Undisclosed | |
| Half Maximal Inhibitory Concentration (IC50) | 26 | nM |
A2780 cells
|
Ovarian endometrioid adenocarcinoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 26 | nM |
MDA-MB-435 cells
|
Amelanotic melanoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 2600 | nM |
LNCaP cells
|
Prostate carcinoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 2600 | nM |
Cancer cells
|
Multiple myeloma, Plasma cell myeloma
|
Undisclosed | |
| Half Maximal Growth Inhibitory Concentration (GI50) | 264.24 | nM |
DU145 cells
|
Prostate carcinoma
|
||
| Half Maximal Growth Inhibitory Concentration (GI50) | 2650 | nM |
MDCK-II cells
|
Normal
|
||
| Half Maximal Inhibitory Concentration (IC50) | 27.6 | nM |
PC-3 cells
|
Prostate carcinoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 270 | nM |
SMMC-7721 cells
|
Hepatocellular carcinoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | >277.93 | nM | Undisclosed | Undisclosed | Undisclosed | |
| Half Maximal Inhibitory Concentration (IC50) | 28.2 | nM | Undisclosed | Undisclosed | Undisclosed | |
| Half Maximal Activity Concentration (AC50) | 281.8 | nM | Undisclosed | Undisclosed | Undisclosed | |
| Half Maximal Activity Concentration (AC50) | 281.8 | nM | Undisclosed | Undisclosed | Undisclosed | |
| Half Maximal Inhibitory Concentration (IC50) | 28110 | nM |
PC-3 cells
|
Prostate carcinoma
|
||
| Half Maximal Growth Inhibitory Concentration (GI50) | 287.74 | nM |
SK-OV-3 cells
|
Ovarian serous adenocarcinoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 29 | nM |
MCF-7 cells
|
Invasive breast carcinoma of no special type
|
||
| Half Maximal Inhibitory Concentration (IC50) | 29.3 | nM |
SNU-475 cells
|
Hepatocellular carcinoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 2916 | nM |
Cancer cells
|
Multiple myeloma, Plasma cell myeloma
|
Undisclosed | |
| Half Maximal Inhibitory Concentration (IC50) | 299 | nM |
P388/ADR cells
|
Lymphoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 3 | nM |
CCRF-CEM cells
|
T acute lymphoblastic leukemia
|
||
| Half Maximal Inhibitory Concentration (IC50) | 3 | nM |
KB cells
|
Human papillomavirus-related endocervical adenocarcinoma
|
||
| Half Maximal Growth Inhibitory Concentration (GI50) | 3 | nM |
NCI-H460 cells
|
Lung large cell carcinoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 3 | nM |
SMMC-7721 cells
|
Hepatocellular carcinoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 3.1 | nM |
A2780 cells
|
Ovarian endometrioid adenocarcinoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 3.3 | nM |
KB cells
|
Human papillomavirus-related endocervical adenocarcinoma
|
||
| Half Maximal Effective Concentration (EC50) | 3.4 | nM |
A2780 cells
|
Ovarian endometrioid adenocarcinoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 3.4 | nM |
L1210 cells
|
Lymphoblastic leukemia
|
||
| Half Maximal Inhibitory Concentration (IC50) | 3.4 | nM |
L1210 cells
|
Lymphoblastic leukemia
|
||
| Half Maximal Inhibitory Concentration (IC50) | 3.4 | nM |
L1210 cells
|
Lymphoblastic leukemia
|
||
| Half Maximal Inhibitory Concentration (IC50) | 3.5 | nM |
A-375 cells
|
Amelanotic melanoma
|
||
| Half Maximal Effective Concentration (EC50) | 3.9 | nM |
A2780 cells
|
Ovarian endometrioid adenocarcinoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 30 | nM |
A549 cells
|
Lung adenocarcinoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 30 | nM |
A549 cells
|
Lung adenocarcinoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 30 | nM |
A2780 cells
|
Ovarian endometrioid adenocarcinoma
|
||
| Half Maximal Growth Inhibitory Concentration (GI50) | 30 | nM |
LLC-PK1 cells
|
Normal
|
||
| Half Maximal Inhibitory Concentration (IC50) | 30 | nM |
OE33 cells
|
Barrett adenocarcinoma, Adenocarcinoma of the esophagus
|
||
| Half Maximal Inhibitory Concentration (IC50) | 30 | nM | Undisclosed | Undisclosed | Undisclosed | |
| Half Maximal Inhibitory Concentration (IC50) | 300 | nM |
MCF-7 cells
|
Invasive breast carcinoma of no special type
|
||
| Half Maximal Growth Inhibitory Concentration (GI50) | 300 | nM |
Cancer cells
|
Multiple myeloma, Plasma cell myeloma
|
Undisclosed | |
| Half Maximal Growth Inhibitory Concentration (GI50) | 300 | nM |
Cancer cells
|
Multiple myeloma, Plasma cell myeloma
|
Undisclosed | |
| Half Maximal Growth Inhibitory Concentration (GI50) | 300 | nM |
Cancer cells
|
Multiple myeloma, Plasma cell myeloma
|
Undisclosed | |
| Half Maximal Growth Inhibitory Concentration (GI50) | 300 | nM |
Cancer cells
|
Multiple myeloma, Plasma cell myeloma
|
Undisclosed | |
| Half Maximal Growth Inhibitory Concentration (GI50) | 300 | nM |
Cancer cells
|
Multiple myeloma, Plasma cell myeloma
|
Undisclosed | |
| Half Maximal Growth Inhibitory Concentration (GI50) | 300 | nM |
Cancer cells
|
Multiple myeloma, Plasma cell myeloma
|
Undisclosed | |
| Half Maximal Inhibitory Concentration (IC50) | 300 | nM |
L02 cells
|
Human papillomavirus-related endocervical adenocarcinoma
|
||
| Half Maximal Activity Concentration (AC50) | >30000 | nM | Undisclosed | Undisclosed | Undisclosed | |
| Half Maximal Activity Concentration (AC50) | >30000 | nM | Undisclosed | Undisclosed | Undisclosed | |
| Half Maximal Activity Concentration (AC50) | >30000 | nM | Undisclosed | Undisclosed | Undisclosed | |
| Half Maximal Activity Concentration (AC50) | >30000 | nM | Undisclosed | Undisclosed | Undisclosed | |
| Half Maximal Activity Concentration (AC50) | >30000 | nM | Undisclosed | Undisclosed | Undisclosed | |
| Half Maximal Activity Concentration (AC50) | >30000 | nM | Undisclosed | Undisclosed | Undisclosed | |
| Half Maximal Activity Concentration (AC50) | >30000 | nM | Undisclosed | Undisclosed | Undisclosed | |
| Half Maximal Activity Concentration (AC50) | >30000 | nM | Undisclosed | Undisclosed | Undisclosed | |
| Half Maximal Activity Concentration (AC50) | >30000 | nM | Undisclosed | Undisclosed | Undisclosed | |
| Half Maximal Activity Concentration (AC50) | >30000 | nM | Undisclosed | Undisclosed | Undisclosed | |
| Half Maximal Activity Concentration (AC50) | >30000 | nM | Undisclosed | Undisclosed | Undisclosed | |
| Half Maximal Activity Concentration (AC50) | >30000 | nM | Undisclosed | Undisclosed | Undisclosed | |
| Half Maximal Activity Concentration (AC50) | >30000 | nM | Undisclosed | Undisclosed | Undisclosed | |
| Half Maximal Activity Concentration (AC50) | >30000 | nM | Undisclosed | Undisclosed | Undisclosed | |
| Half Maximal Activity Concentration (AC50) | >30000 | nM | Undisclosed | Undisclosed | Undisclosed | |
| Half Maximal Activity Concentration (AC50) | >30000 | nM | Undisclosed | Undisclosed | Undisclosed | |
| Half Maximal Activity Concentration (AC50) | >30000 | nM | Undisclosed | Undisclosed | Undisclosed | |
| Half Maximal Activity Concentration (AC50) | >30000 | nM | Undisclosed | Undisclosed | Undisclosed | |
| Half Maximal Activity Concentration (AC50) | >30000 | nM | Undisclosed | Undisclosed | Undisclosed | |
| Half Maximal Activity Concentration (AC50) | >30000 | nM | Undisclosed | Undisclosed | Undisclosed | |
| Half Maximal Activity Concentration (AC50) | >30000 | nM | Undisclosed | Undisclosed | Undisclosed | |
| Half Maximal Activity Concentration (AC50) | >30000 | nM | Undisclosed | Undisclosed | Undisclosed | |
| Half Maximal Activity Concentration (AC50) | >30000 | nM | Undisclosed | Undisclosed | Undisclosed | |
| Half Maximal Activity Concentration (AC50) | >30000 | nM | Undisclosed | Undisclosed | Undisclosed | |
| Half Maximal Activity Concentration (AC50) | >30000 | nM | Undisclosed | Undisclosed | Undisclosed | |
| Half Maximal Activity Concentration (AC50) | >30000 | nM | Undisclosed | Undisclosed | Undisclosed | |
| Half Maximal Activity Concentration (AC50) | >30000 | nM | Undisclosed | Undisclosed | Undisclosed | |
| Half Maximal Inhibitory Concentration (IC50) | 303.2 | nM |
Cancer cells
|
Multiple myeloma, Plasma cell myeloma
|
Undisclosed | |
| Half Maximal Growth Inhibitory Concentration (GI50) | 3047.89 | nM |
TK-10 cells
|
Renal carcinoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 308 | nM |
Cancer cells
|
Multiple myeloma, Plasma cell myeloma
|
Undisclosed | |
| Half Maximal Inhibitory Concentration (IC50) | 31 | nM |
HEK293 cells
|
Normal
|
||
| Half Maximal Inhibitory Concentration (IC50) | 311 | nM |
A2780 ADR cells
|
Ovarian endometrioid adenocarcinoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 3120 | nM |
HEK-293T cells
|
Normal
|
||
| Half Maximal Growth Inhibitory Concentration (GI50) | 316.23 | nM |
Cancer cells
|
Multiple myeloma, Plasma cell myeloma
|
Undisclosed | |
| Half Maximal Growth Inhibitory Concentration (GI50) | 316.23 | nM |
Cancer cells
|
Multiple myeloma, Plasma cell myeloma
|
Undisclosed | |
| Half Maximal Growth Inhibitory Concentration (GI50) | 316.23 | nM |
Cancer cells
|
Multiple myeloma, Plasma cell myeloma
|
Undisclosed | |
| Half Maximal Growth Inhibitory Concentration (GI50) | 316.23 | nM |
Cancer cells
|
Multiple myeloma, Plasma cell myeloma
|
Undisclosed | |
| Half Maximal Growth Inhibitory Concentration (GI50) | 316.23 | nM |
Cancer cells
|
Multiple myeloma, Plasma cell myeloma
|
Undisclosed | |
| Half Maximal Growth Inhibitory Concentration (GI50) | 316.23 | nM |
Cancer cells
|
Multiple myeloma, Plasma cell myeloma
|
Undisclosed | |
| Half Maximal Growth Inhibitory Concentration (GI50) | 316.23 | nM |
Cancer cells
|
Multiple myeloma, Plasma cell myeloma
|
Undisclosed | |
| Half Maximal Growth Inhibitory Concentration (GI50) | 316.23 | nM |
Cancer cells
|
Multiple myeloma, Plasma cell myeloma
|
Undisclosed | |
| Half Maximal Growth Inhibitory Concentration (GI50) | 316.23 | nM |
Cancer cells
|
Multiple myeloma, Plasma cell myeloma
|
Undisclosed | |
| Half Maximal Growth Inhibitory Concentration (GI50) | 316.23 | nM |
Cancer cells
|
Multiple myeloma, Plasma cell myeloma
|
Undisclosed | |
| Half Maximal Growth Inhibitory Concentration (GI50) | 316.23 | nM |
Cancer cells
|
Multiple myeloma, Plasma cell myeloma
|
Undisclosed | |
| Half Maximal Growth Inhibitory Concentration (GI50) | 316.23 | nM |
Cancer cells
|
Multiple myeloma, Plasma cell myeloma
|
Undisclosed | |
| Half Maximal Growth Inhibitory Concentration (GI50) | 316.23 | nM | Undisclosed | Undisclosed | Undisclosed | |
| Half Maximal Growth Inhibitory Concentration (GI50) | 316.23 | nM | Undisclosed | Undisclosed | Undisclosed | |
| Half Maximal Growth Inhibitory Concentration (GI50) | 316.23 | nM | Undisclosed | Undisclosed | Undisclosed | |
| Half Maximal Inhibitory Concentration (IC50) | 3162.28 | nM | Undisclosed | Undisclosed | Undisclosed | |
| Half Maximal Growth Inhibitory Concentration (GI50) | 320 | nM |
Cancer cells
|
Multiple myeloma, Plasma cell myeloma
|
Undisclosed | |
| Half Maximal Growth Inhibitory Concentration (GI50) | 320 | nM |
Cancer cells
|
Multiple myeloma, Plasma cell myeloma
|
Undisclosed | |
| Half Maximal Growth Inhibitory Concentration (GI50) | 320 | nM |
Cancer cells
|
Multiple myeloma, Plasma cell myeloma
|
Undisclosed | |
| Half Maximal Growth Inhibitory Concentration (GI50) | 320 | nM |
Cancer cells
|
Multiple myeloma, Plasma cell myeloma
|
Undisclosed | |
| Half Maximal Growth Inhibitory Concentration (GI50) | 320 | nM |
Cancer cells
|
Multiple myeloma, Plasma cell myeloma
|
Undisclosed | |
| Half Maximal Growth Inhibitory Concentration (GI50) | 320 | nM |
Cancer cells
|
Multiple myeloma, Plasma cell myeloma
|
Undisclosed | |
| Half Maximal Growth Inhibitory Concentration (GI50) | 320 | nM |
Cancer cells
|
Multiple myeloma, Plasma cell myeloma
|
Undisclosed | |
| Half Maximal Growth Inhibitory Concentration (GI50) | 320 | nM |
Cancer cells
|
Multiple myeloma, Plasma cell myeloma
|
Undisclosed | |
| Half Maximal Growth Inhibitory Concentration (GI50) | 320 | nM |
Cancer cells
|
Multiple myeloma, Plasma cell myeloma
|
Undisclosed | |
| Half Maximal Growth Inhibitory Concentration (GI50) | 320 | nM |
Cancer cells
|
Multiple myeloma, Plasma cell myeloma
|
Undisclosed | |
| Half Maximal Growth Inhibitory Concentration (GI50) | 332.66 | nM |
Malme-3M cells
|
Melanoma
|
||
| Half Maximal Growth Inhibitory Concentration (GI50) | 340 | nM |
MDCK-II cells
|
Normal
|
||
| Half Maximal Inhibitory Concentration (IC50) | 35 | nM |
KB cells
|
Human papillomavirus-related endocervical adenocarcinoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 35.8 | nM |
HeLa cells
|
Human papillomavirus-related endocervical adenocarcinoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 35.9 | nM |
SNU-182 cells
|
Adult hepatocellular carcinoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 350 | nM |
KB cells
|
Human papillomavirus-related endocervical adenocarcinoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 350 | nM |
HCT-8 cells
|
Ileocecal adenocarcinoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 350 | nM |
HCT-8 cells
|
Ileocecal adenocarcinoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 357.51 | nM |
Cancer cells
|
Multiple myeloma, Plasma cell myeloma
|
Undisclosed | |
| Half Maximal Inhibitory Concentration (IC50) | 36 | nM |
HeLa cells
|
Human papillomavirus-related endocervical adenocarcinoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 36 | nM |
KB cells
|
Human papillomavirus-related endocervical adenocarcinoma
|
||
| Half Maximal Growth Inhibitory Concentration (GI50) | 36 | nM |
HCT-8 cells
|
Ileocecal adenocarcinoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 36.83 | nM |
A549 cells
|
Lung adenocarcinoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 360 | nM |
A549 cells
|
Lung adenocarcinoma
|
||
| Half Maximal Effective Concentration (EC50) | 366.6 | nM |
CCRF-CEM cells
|
T acute lymphoblastic leukemia
|
||
| Half Maximal Inhibitory Concentration (IC50) | 36780 | nM | Undisclosed | Undisclosed | Undisclosed | |
| Half Maximal Inhibitory Concentration (IC50) | 37 | nM |
786-O cells
|
Renal cell carcinoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 3700 | nM |
HepG2 cells
|
Hepatoblastoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 387.43 | nM |
Cancer cells
|
Multiple myeloma, Plasma cell myeloma
|
Undisclosed | |
| Half Maximal Inhibitory Concentration (IC50) | 3900 | nM |
Cancer cells
|
Multiple myeloma, Plasma cell myeloma
|
Undisclosed | |
| Tumor Growth Inhibition (TGI) | 3980 | nM |
Cancer cells
|
Multiple myeloma, Plasma cell myeloma
|
Undisclosed | |
| Tumor Growth Inhibition (TGI) | 3980 | nM |
Cancer cells
|
Multiple myeloma, Plasma cell myeloma
|
Undisclosed | |
| Tumor Growth Inhibition (TGI) | 3980 | nM | Undisclosed | Undisclosed | Undisclosed | |
| Tumor Growth Inhibition (TGI) | 3981.07 | nM |
Cancer cells
|
Multiple myeloma, Plasma cell myeloma
|
Undisclosed | |
| Tumor Growth Inhibition (TGI) | 3981.07 | nM |
Cancer cells
|
Multiple myeloma, Plasma cell myeloma
|
Undisclosed | |
| Tumor Growth Inhibition (TGI) | 3981.07 | nM |
Cancer cells
|
Multiple myeloma, Plasma cell myeloma
|
Undisclosed | |
| Tumor Growth Inhibition (TGI) | 3981.07 | nM | Undisclosed | Undisclosed | Undisclosed | |
| Half Maximal Activity Concentration (AC50) | 3981.1 | nM | Undisclosed | Undisclosed | Undisclosed | |
| Half Maximal Activity Concentration (AC50) | 39810.7 | nM | Undisclosed | Undisclosed | Undisclosed | |
| Half Maximal Inhibitory Concentration (IC50) | 4 | nM |
K562 cells
|
Blast phase chronic myelogenous leukemia, BCR-ABL1 positive, Chronic myeloid leukemia
|
||
| Half Maximal Growth Inhibitory Concentration (GI50) | 4 | nM |
KB cells
|
Human papillomavirus-related endocervical adenocarcinoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 4 | nM |
KB cells
|
Human papillomavirus-related endocervical adenocarcinoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 4 | nM |
C2C12 cells
|
Normal
|
||
| Half Maximal Inhibitory Concentration (IC50) | 4 | nM |
PT-45 cells
|
Pancreatic carcinoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 4 | nM |
PT-45 cells
|
Pancreatic carcinoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 4.2 | nM |
MCF-7 cells
|
Invasive breast carcinoma of no special type
|
||
| Half Maximal Inhibitory Concentration (IC50) | 4.2 | nM |
Bel-7402 cells
|
Hepatoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 4.3 | nM |
HeLa cells
|
Human papillomavirus-related endocervical adenocarcinoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 4.5 | nM |
MDA-MB-231 cells
|
Breast adenocarcinoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 4.5 | nM |
MDA-MB-231 cells
|
Breast adenocarcinoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 4.5 | nM |
Cancer cells
|
Multiple myeloma, Plasma cell myeloma
|
Undisclosed | |
| Half Maximal Inhibitory Concentration (IC50) | 4.5 | nM |
P388/ADR cells
|
Lymphoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 4.7 | nM |
P388 cells
|
Lymphoma
|
||
| Median Effective Dose (ED50) | 4.8 | nM |
A549 cells
|
Lung adenocarcinoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 4.85 | nM |
L1210 cells
|
Lymphoblastic leukemia
|
||
| Half Maximal Inhibitory Concentration (IC50) | 4.9 | nM |
MES-SA cells
|
Uterine sarcoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 40 | nM |
A549 cells
|
Lung adenocarcinoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 40 | nM |
ZR-75-1 cells
|
Invasive breast carcinoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 40 | nM |
HeLa cells
|
Human papillomavirus-related endocervical adenocarcinoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 40 | nM |
Bel-7402 cells
|
Hepatoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 40.9 | nM |
SNU-387 cells
|
Hepatocellular carcinoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 400 | nM | Undisclosed | Undisclosed | Undisclosed | |
| Tumor Growth Inhibition (TGI) | 4000 | nM |
Cancer cells
|
Multiple myeloma, Plasma cell myeloma
|
Undisclosed | |
| Tumor Growth Inhibition (TGI) | 4000 | nM |
Cancer cells
|
Multiple myeloma, Plasma cell myeloma
|
Undisclosed | |
| Half Maximal Inhibitory Concentration (IC50) | <40000 | nM |
Cancer cells
|
Multiple myeloma, Plasma cell myeloma
|
Undisclosed | |
| Half Maximal Inhibitory Concentration (IC50) | <40000 | nM |
Cancer cells
|
Multiple myeloma, Plasma cell myeloma
|
Undisclosed | |
| Half Maximal Inhibitory Concentration (IC50) | <40000 | nM |
HeLa S3 cells
|
Endocervical adenocarcinoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 4100 | nM |
HeLa cells
|
Human papillomavirus-related endocervical adenocarcinoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 417 | nM | Undisclosed | Undisclosed | Undisclosed | |
| Half Maximal Inhibitory Concentration (IC50) | 4280 | nM | Undisclosed | Undisclosed | Undisclosed | |
| Half Maximal Growth Inhibitory Concentration (GI50) | 429.54 | nM |
SNB-75 cells
|
Glioblastoma
|
||
| Half Maximal Effective Concentration (EC50) | 43 | nM |
T47D cells
|
Invasive breast carcinoma of no special type
|
||
| Half Maximal Growth Inhibitory Concentration (GI50) | 430 | nM |
MDCK-II cells
|
Normal
|
||
| Half Maximal Inhibitory Concentration (IC50) | 4300 | nM |
MCF-7 cells
|
Invasive breast carcinoma of no special type
|
||
| Half Maximal Inhibitory Concentration (IC50) | 435.85 | nM |
Cancer cells
|
Multiple myeloma, Plasma cell myeloma
|
Undisclosed | |
| Half Maximal Inhibitory Concentration (IC50) | 44000 | nM |
HEK293 cells
|
Normal
|
||
| Half Maximal Inhibitory Concentration (IC50) | 46.7 | nM |
SNU-398 cells
|
Hepatocellular carcinoma
|
||
| Half Maximal Effective Concentration (EC50) | 47 | nM | Undisclosed | Undisclosed | Undisclosed | |
| Half Maximal Inhibitory Concentration (IC50) | 4730 | nM |
Cancer cells
|
Multiple myeloma, Plasma cell myeloma
|
Undisclosed | |
| Half Maximal Inhibitory Concentration (IC50) | 4737 | nM |
Cancer cells
|
Multiple myeloma, Plasma cell myeloma
|
Undisclosed | |
| Half Maximal Inhibitory Concentration (IC50) | 48.43 | nM |
HCT116 cells
|
Colon carcinoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 480 | nM |
Lu1 cells
|
Multiple myeloma, Plasma cell myeloma
|
Undisclosed | |
| Half Maximal Inhibitory Concentration (IC50) | 49 | nM | Undisclosed | Undisclosed | Undisclosed | |
| Half Maximal Inhibitory Concentration (IC50) | 5 | nM |
HeLa cells
|
Human papillomavirus-related endocervical adenocarcinoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 5 | nM |
HeLa cells
|
Human papillomavirus-related endocervical adenocarcinoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 5 | nM |
KB cells
|
Human papillomavirus-related endocervical adenocarcinoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 5 | nM |
KB cells
|
Human papillomavirus-related endocervical adenocarcinoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 5.1 | nM |
C2C12 cells
|
Normal
|
||
| Half Maximal Inhibitory Concentration (IC50) | 5.4 | nM |
Cancer cells
|
Multiple myeloma, Plasma cell myeloma
|
Undisclosed | |
| Half Maximal Inhibitory Concentration (IC50) | 5.7 | nM |
CAKI-1 cells
|
Clear cell renal cell carcinoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 5.9 | nM |
HeLa cells
|
Human papillomavirus-related endocervical adenocarcinoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 50 | nM |
OE19 cells
|
Esophageal adenocarcinoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 50 | nM |
KB cells
|
Human papillomavirus-related endocervical adenocarcinoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 50 | nM |
KB cells
|
Human papillomavirus-related endocervical adenocarcinoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 50 | nM | Undisclosed | Undisclosed | Undisclosed | |
| Half Maximal Inhibitory Concentration (IC50) | 50.12 | nM | Undisclosed | Undisclosed | Undisclosed | |
| Half Maximal Inhibitory Concentration (IC50) | >500 | nM |
BXPC-3 cells
|
Pancreatic ductal adenocarcinoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 500 | nM |
B16 cells
|
Melanoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 500 | nM | Undisclosed | Undisclosed | Undisclosed | |
| Half Maximal Activity Concentration (AC50) | 50118.7 | nM | Undisclosed | Undisclosed | Undisclosed | |
| Half Maximal Inhibitory Concentration (IC50) | 50300 | nM |
Cancer cells
|
Multiple myeloma, Plasma cell myeloma
|
Undisclosed | |
| Half Maximal Inhibitory Concentration (IC50) | 50300 | nM |
Cancer cells
|
Multiple myeloma, Plasma cell myeloma
|
Undisclosed | |
| Half Maximal Inhibitory Concentration (IC50) | 5060 | nM |
Cancer cells
|
Multiple myeloma, Plasma cell myeloma
|
Undisclosed | |
| Half Maximal Inhibitory Concentration (IC50) | 510 | nM |
MCF-7 cells
|
Invasive breast carcinoma of no special type
|
||
| Half Maximal Inhibitory Concentration (IC50) | 52210 | nM |
SMMC-7721 cells
|
Hepatocellular carcinoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 53 | nM |
A549 cells
|
Lung adenocarcinoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 5300 | nM |
HT-29 cells
|
Colon adenocarcinoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 5300 | nM | Undisclosed | Undisclosed | Undisclosed | |
| Half Maximal Inhibitory Concentration (IC50) | 5310 | nM |
PC-3 cells
|
Prostate carcinoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 5360 | nM |
K562 cells
|
Blast phase chronic myelogenous leukemia, BCR-ABL1 positive, Chronic myeloid leukemia
|
||
| Half Maximal Inhibitory Concentration (IC50) | 54.72 | nM |
BT-549 cells
|
Breast ductal carcinoma
|
||
| Half Maximal Effective Concentration (EC50) | 55 | nM | Undisclosed | Undisclosed | Undisclosed | |
| Half Maximal Inhibitory Concentration (IC50) | 559.21 | nM |
Cancer cells
|
Multiple myeloma, Plasma cell myeloma
|
Undisclosed | |
| Half Maximal Inhibitory Concentration (IC50) | 56 | nM |
A549 cells
|
Lung adenocarcinoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 560 | nM |
A549 cells
|
Lung adenocarcinoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 561 | nM |
A549 cells
|
Lung adenocarcinoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 570 | nM |
Cancer cells
|
Multiple myeloma, Plasma cell myeloma
|
Undisclosed | |
| Half Maximal Inhibitory Concentration (IC50) | 5720 | nM |
Cancer cells
|
Multiple myeloma, Plasma cell myeloma
|
Undisclosed | |
| Half Maximal Activity Concentration (AC50) | 5726 | nM | Undisclosed | Undisclosed | Undisclosed | |
| Half Maximal Effective Concentration (EC50) | 58 | nM |
HCT116 cells
|
Colon carcinoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 58 | nM | Undisclosed | Undisclosed | Undisclosed | |
| Half Maximal Inhibitory Concentration (IC50) | 58 | nM | Undisclosed | Undisclosed | Undisclosed | |
| Half Maximal Inhibitory Concentration (IC50) | 58 | nM | Undisclosed | Undisclosed | Undisclosed | |
| Half Maximal Growth Inhibitory Concentration (GI50) | 583.45 | nM |
OVCAR-4 cells
|
Ovarian adenocarcinoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 5900 | nM |
Cancer cells
|
Multiple myeloma, Plasma cell myeloma
|
Undisclosed | |
| Half Maximal Effective Concentration (EC50) | 597.2 | nM |
CCRF-CEM cells
|
T acute lymphoblastic leukemia
|
||
| Half Maximal Inhibitory Concentration (IC50) | 5970 | nM |
HEL cells
|
Erythroleukemia
|
||
| Half Maximal Growth Inhibitory Concentration (GI50) | 6 | nM |
HCT116 cells
|
Colon carcinoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 6 | nM |
K562 cells
|
Blast phase chronic myelogenous leukemia, BCR-ABL1 positive, Chronic myeloid leukemia
|
||
| Half Maximal Inhibitory Concentration (IC50) | 6 | nM |
MDA-MB-231 cells
|
Breast adenocarcinoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 6 | nM |
MDA-MB-231 cells
|
Breast adenocarcinoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 6 | nM |
KB cells
|
Human papillomavirus-related endocervical adenocarcinoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 6 | nM |
KB cells
|
Human papillomavirus-related endocervical adenocarcinoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 6 | nM |
L1210 cells
|
Lymphoblastic leukemia
|
||
| Half Maximal Inhibitory Concentration (IC50) | 6.07 | nM |
KB cells
|
Human papillomavirus-related endocervical adenocarcinoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 6.1 | nM |
HeLa cells
|
Human papillomavirus-related endocervical adenocarcinoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 6.1 | nM |
LNCaP cells
|
Prostate carcinoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 6.2 | nM |
HeLa cells
|
Human papillomavirus-related endocervical adenocarcinoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 6.5 | nM |
HeLa cells
|
Human papillomavirus-related endocervical adenocarcinoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 6.5 | nM |
SMMC-7721 cells
|
Hepatocellular carcinoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 6.5 | nM | Undisclosed | Undisclosed | Undisclosed | |
| Half Maximal Inhibitory Concentration (IC50) | 6.7 | nM |
KB cells
|
Human papillomavirus-related endocervical adenocarcinoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 60 | nM |
A549 cells
|
Lung adenocarcinoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 60 | nM |
HL-60 cells
|
Acute myeloblastic leukemia with maturation, Adult acute myeloid leukemia with maturation
|
||
| Half Maximal Inhibitory Concentration (IC50) | 60 | nM |
L02 cells
|
Human papillomavirus-related endocervical adenocarcinoma
|
||
| Half Maximal Effective Concentration (EC50) | 60.88 | nM |
Cancer cells
|
Multiple myeloma, Plasma cell myeloma
|
Undisclosed | |
| Half Maximal Growth Inhibitory Concentration (GI50) | 605.34 | nM |
Cancer cells
|
Multiple myeloma, Plasma cell myeloma
|
Undisclosed | |
| Half Maximal Inhibitory Concentration (IC50) | 61 | nM |
A549 cells
|
Lung adenocarcinoma
|
||
| Half Maximal Effective Concentration (EC50) | 6200 | nM |
C6 cells
|
Glioma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 62800 | nM |
Cancer cells
|
Multiple myeloma, Plasma cell myeloma
|
Undisclosed | |
| Half Maximal Effective Concentration (EC50) | 63 | nM | Undisclosed | Undisclosed | Undisclosed | |
| Tumor Growth Inhibition (TGI) | 6300 | nM |
Cancer cells
|
Multiple myeloma, Plasma cell myeloma
|
Undisclosed | |
| Tumor Growth Inhibition (TGI) | 6300 | nM |
Cancer cells
|
Multiple myeloma, Plasma cell myeloma
|
Undisclosed | |
| Tumor Growth Inhibition (TGI) | 6300 | nM |
Cancer cells
|
Multiple myeloma, Plasma cell myeloma
|
Undisclosed | |
| Tumor Growth Inhibition (TGI) | 6300 | nM |
Cancer cells
|
Multiple myeloma, Plasma cell myeloma
|
Undisclosed | |
| Tumor Growth Inhibition (TGI) | 6309.57 | nM |
Cancer cells
|
Multiple myeloma, Plasma cell myeloma
|
Undisclosed | |
| Tumor Growth Inhibition (TGI) | 6309.57 | nM |
Cancer cells
|
Multiple myeloma, Plasma cell myeloma
|
Undisclosed | |
| Tumor Growth Inhibition (TGI) | 6309.57 | nM |
Cancer cells
|
Multiple myeloma, Plasma cell myeloma
|
Undisclosed | |
| Tumor Growth Inhibition (TGI) | 6309.57 | nM |
Cancer cells
|
Multiple myeloma, Plasma cell myeloma
|
Undisclosed | |
| Tumor Growth Inhibition (TGI) | 6309.57 | nM |
Cancer cells
|
Multiple myeloma, Plasma cell myeloma
|
Undisclosed | |
| Tumor Growth Inhibition (TGI) | 6309.57 | nM |
Cancer cells
|
Multiple myeloma, Plasma cell myeloma
|
Undisclosed | |
| Tumor Growth Inhibition (TGI) | 6309.57 | nM |
Cancer cells
|
Multiple myeloma, Plasma cell myeloma
|
Undisclosed | |
| Tumor Growth Inhibition (TGI) | 6309.57 | nM | Undisclosed | Undisclosed | Undisclosed | |
| Tumor Growth Inhibition (TGI) | 6310 | nM |
Cancer cells
|
Multiple myeloma, Plasma cell myeloma
|
Undisclosed | |
| Tumor Growth Inhibition (TGI) | 6310 | nM |
Cancer cells
|
Multiple myeloma, Plasma cell myeloma
|
Undisclosed | |
| Tumor Growth Inhibition (TGI) | 6310 | nM |
Cancer cells
|
Multiple myeloma, Plasma cell myeloma
|
Undisclosed | |
| Tumor Growth Inhibition (TGI) | 6310 | nM |
Cancer cells
|
Multiple myeloma, Plasma cell myeloma
|
Undisclosed | |
| Tumor Growth Inhibition (TGI) | 6310 | nM |
Cancer cells
|
Multiple myeloma, Plasma cell myeloma
|
Undisclosed | |
| Tumor Growth Inhibition (TGI) | 6310 | nM |
Cancer cells
|
Multiple myeloma, Plasma cell myeloma
|
Undisclosed | |
| Half Maximal Inhibitory Concentration (IC50) | 650 | nM |
HaCaT cells
|
Normal
|
||
| Half Maximal Growth Inhibitory Concentration (GI50) | 657.66 | nM |
BT-549 cells
|
Breast ductal carcinoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 6600 | nM |
Cancer cells
|
Multiple myeloma, Plasma cell myeloma
|
Undisclosed | |
| Half Maximal Inhibitory Concentration (IC50) | >67541 | nM | Undisclosed | Undisclosed | Undisclosed | |
| Half Maximal Growth Inhibitory Concentration (GI50) | 6860 | nM |
Cancer cells
|
Multiple myeloma, Plasma cell myeloma
|
Undisclosed | |
| Half Maximal Inhibitory Concentration (IC50) | 690 | nM |
HepG2 cells
|
Hepatoblastoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 7 | nM |
HCT116 cells
|
Colon carcinoma
|
||
| Half Maximal Growth Inhibitory Concentration (GI50) | 7 | nM |
A549 cells
|
Lung adenocarcinoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 7 | nM |
HT-29 cells
|
Colon adenocarcinoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 7.2 | nM | Undisclosed | Undisclosed | Undisclosed | |
| Half Maximal Inhibitory Concentration (IC50) | 7.6 | nM |
TERT-RPE1 cells
|
Normal
|
||
| Half Maximal Inhibitory Concentration (IC50) | 7.9 | nM |
KB cells
|
Human papillomavirus-related endocervical adenocarcinoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 70 | nM |
HepG2 cells
|
Hepatoblastoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 70 | nM |
PC-3 cells
|
Prostate carcinoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 700 | nM | Undisclosed | Undisclosed | Undisclosed | |
| Half Maximal Inhibitory Concentration (IC50) | 70000 | nM |
HeLa cells
|
Human papillomavirus-related endocervical adenocarcinoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 7100 | nM |
MKN-28 cells
|
Gastric epithelial carcinoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 71830 | nM |
DU145 cells
|
Prostate carcinoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 72.3 | nM |
DU145 cells
|
Prostate carcinoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 75 | nM |
MX1 cells
|
Breast carcinoma
|
||
| Half Maximal Growth Inhibitory Concentration (GI50) | 7500 | nM |
Cancer cells
|
Multiple myeloma, Plasma cell myeloma
|
Undisclosed | |
| Half Maximal Inhibitory Concentration (IC50) | 7500 | nM |
Cancer cells
|
Multiple myeloma, Plasma cell myeloma
|
Undisclosed | |
| Half Maximal Inhibitory Concentration (IC50) | 7860 | nM |
Cancer cells
|
Multiple myeloma, Plasma cell myeloma
|
Undisclosed | |
| Half Maximal Inhibitory Concentration (IC50) | 7860 | nM |
HCT-8 cells
|
Ileocecal adenocarcinoma
|
||
| Tumor Growth Inhibition (TGI) | 7900 | nM |
Melanoma cells
|
Multiple myeloma, Plasma cell myeloma
|
Undisclosed | |
| Tumor Growth Inhibition (TGI) | 7900 | nM |
Melanoma cells
|
Multiple myeloma, Plasma cell myeloma
|
Undisclosed | |
| Tumor Growth Inhibition (TGI) | 7900 | nM |
Cancer cells
|
Multiple myeloma, Plasma cell myeloma
|
Undisclosed | |
| Tumor Growth Inhibition (TGI) | 7900 | nM |
Cancer cells
|
Multiple myeloma, Plasma cell myeloma
|
Undisclosed | |
| Tumor Growth Inhibition (TGI) | 7940 | nM |
Melanoma cells
|
Multiple myeloma, Plasma cell myeloma
|
Undisclosed | |
| Tumor Growth Inhibition (TGI) | 7940 | nM |
Melanoma cells
|
Multiple myeloma, Plasma cell myeloma
|
Undisclosed | |
| Tumor Growth Inhibition (TGI) | 7940 | nM |
Melanoma cells
|
Multiple myeloma, Plasma cell myeloma
|
Undisclosed | |
| Tumor Growth Inhibition (TGI) | 7940 | nM |
Cancer cells
|
Multiple myeloma, Plasma cell myeloma
|
Undisclosed | |
| Tumor Growth Inhibition (TGI) | 7940 | nM |
Cancer cells
|
Multiple myeloma, Plasma cell myeloma
|
Undisclosed | |
| Tumor Growth Inhibition (TGI) | 7940 | nM |
Cancer cells
|
Multiple myeloma, Plasma cell myeloma
|
Undisclosed | |
| Tumor Growth Inhibition (TGI) | 7943.28 | nM |
Melanoma cells
|
Multiple myeloma, Plasma cell myeloma
|
Undisclosed | |
| Tumor Growth Inhibition (TGI) | 7943.28 | nM |
Melanoma cells
|
Multiple myeloma, Plasma cell myeloma
|
Undisclosed | |
| Tumor Growth Inhibition (TGI) | 7943.28 | nM |
Melanoma cells
|
Multiple myeloma, Plasma cell myeloma
|
Undisclosed | |
| Tumor Growth Inhibition (TGI) | 7943.28 | nM |
Cancer cells
|
Multiple myeloma, Plasma cell myeloma
|
Undisclosed | |
| Tumor Growth Inhibition (TGI) | 7943.28 | nM |
Cancer cells
|
Multiple myeloma, Plasma cell myeloma
|
Undisclosed | |
| Tumor Growth Inhibition (TGI) | 7943.28 | nM |
Cancer cells
|
Multiple myeloma, Plasma cell myeloma
|
Undisclosed | |
| Tumor Growth Inhibition (TGI) | 7943.28 | nM |
Cancer cells
|
Multiple myeloma, Plasma cell myeloma
|
Undisclosed | |
| Tumor Growth Inhibition (TGI) | 7943.28 | nM | Undisclosed | Undisclosed | Undisclosed | |
| Half Maximal Inhibitory Concentration (IC50) | 8.5 | nM |
DU145 cells
|
Prostate carcinoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 80 | nM |
Cancer cells
|
Multiple myeloma, Plasma cell myeloma
|
Undisclosed | |
| Half Maximal Inhibitory Concentration (IC50) | 80 | nM |
BNL cells
|
Multiple myeloma, Plasma cell myeloma
|
Undisclosed | |
| Half Maximal Inhibitory Concentration (IC50) | 800 | nM |
A549 cells
|
Lung adenocarcinoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 800 | nM |
KB cells
|
Human papillomavirus-related endocervical adenocarcinoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 800 | nM |
Cancer cells
|
Multiple myeloma, Plasma cell myeloma
|
Undisclosed | |
| Half Maximal Inhibitory Concentration (IC50) | >80000 | nM |
Jurkat cells
|
Childhood T acute lymphoblastic leukemia, Precursor T-cell acute lymphoblastic leukemia
|
||
| Half Maximal Inhibitory Concentration (IC50) | >80000 | nM |
HEK-293T cells
|
Normal
|
||
| Half Maximal Inhibitory Concentration (IC50) | >80000 | nM | Undisclosed | Undisclosed | Undisclosed | |
| Half Maximal Inhibitory Concentration (IC50) | 817 | nM | Undisclosed | Undisclosed | Undisclosed | |
| Half Maximal Inhibitory Concentration (IC50) | 840 | nM |
Cancer cells
|
Multiple myeloma, Plasma cell myeloma
|
Undisclosed | |
| Half Maximal Inhibitory Concentration (IC50) | 8571 | nM |
KB-V1 cells
|
Cervical carcinoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 871 | nM |
Cancer cells
|
Multiple myeloma, Plasma cell myeloma
|
Undisclosed | |
| Half Maximal Growth Inhibitory Concentration (GI50) | 89 | nM |
CAL-51 cells
|
Breast carcinoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 890 | nM |
MCF-7 cells
|
Invasive breast carcinoma of no special type
|
||
| Half Maximal Inhibitory Concentration (IC50) | 895 | nM |
A2780 ADR cells
|
Ovarian endometrioid adenocarcinoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 9.3 | nM |
MCF7-VP cells
|
Breast carcinoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 9.3 | nM |
MCF7-VP cells
|
Breast carcinoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 9.42 | nM |
Cancer cells
|
Multiple myeloma, Plasma cell myeloma
|
Undisclosed | |
| Half Maximal Inhibitory Concentration (IC50) | 90 | nM |
Cancer cells
|
Multiple myeloma, Plasma cell myeloma
|
Undisclosed | |
| Half Maximal Inhibitory Concentration (IC50) | 90 | nM |
NCI-H295R cells
|
Adrenal cortex carcinoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 90.1 | nM |
KB cells
|
Human papillomavirus-related endocervical adenocarcinoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 90.1 | nM |
Cancer cells
|
Multiple myeloma, Plasma cell myeloma
|
Undisclosed | |
| Half Maximal Inhibitory Concentration (IC50) | 90.1 | nM |
Cancer cells
|
Multiple myeloma, Plasma cell myeloma
|
Undisclosed | |
| Half Maximal Inhibitory Concentration (IC50) | 90.1 | nM |
Cancer cells
|
Multiple myeloma, Plasma cell myeloma
|
Undisclosed | |
| Half Maximal Inhibitory Concentration (IC50) | 900 | nM |
MCF-7 cells
|
Invasive breast carcinoma of no special type
|
||
| Half Maximal Inhibitory Concentration (IC50) | 900 | nM |
Vero cells
|
Normal
|
||
| Half Maximal Growth Inhibitory Concentration (GI50) | 9091 | nM |
Cancer cells
|
Multiple myeloma, Plasma cell myeloma
|
Undisclosed | |
| Half Maximal Inhibitory Concentration (IC50) | 920 | nM |
MCF-7 cells
|
Invasive breast carcinoma of no special type
|
||
| Half Maximal Inhibitory Concentration (IC50) | 926 | nM |
K562/A02 cells
|
Leukemia
|
||
| Half Maximal Inhibitory Concentration (IC50) | 930 | nM |
A2780 cells
|
Ovarian endometrioid adenocarcinoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 93670 | nM |
HepG2 cells
|
Hepatoblastoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 94950 | nM |
HEK-293T cells
|
Normal
|
||
| Half Maximal Inhibitory Concentration (IC50) | 96.4 | nM |
Cancer cells
|
Multiple myeloma, Plasma cell myeloma
|
Undisclosed | |
| Half Maximal Inhibitory Concentration (IC50) | 96.4 | nM |
Cancer cells
|
Multiple myeloma, Plasma cell myeloma
|
Undisclosed | |
| Half Maximal Inhibitory Concentration (IC50) | 98 | nM |
MCF-7 cells
|
Invasive breast carcinoma of no special type
|
||
| Half Maximal Inhibitory Concentration (IC50) | 9860 | nM |
MDA-MB-231 cells
|
Breast adenocarcinoma
|
||
| Half Maximal Activity Concentration (AC50) | 0.06853 | uM | Undisclosed | Undisclosed | Undisclosed | |
| Half Maximal Activity Concentration (AC50) | 0.1122 | uM | Undisclosed | Undisclosed | Undisclosed | |
| Half Maximal Activity Concentration (AC50) | 0.1367 | uM | Undisclosed | Undisclosed | Undisclosed | |
| Half Maximal Activity Concentration (AC50) | 0.1367 | uM | Undisclosed | Undisclosed | Undisclosed | |
| Half Maximal Activity Concentration (AC50) | 0.1534 | uM | Undisclosed | Undisclosed | Undisclosed | |
| Half Maximal Activity Concentration (AC50) | 0.1721 | uM | Undisclosed | Undisclosed | Undisclosed | |
| Half Maximal Activity Concentration (AC50) | 0.1931 | uM | Undisclosed | Undisclosed | Undisclosed | |
| Half Maximal Activity Concentration (AC50) | 0.2167 | uM | Undisclosed | Undisclosed | Undisclosed | |
| Half Maximal Activity Concentration (AC50) | 0.2818 | uM | Undisclosed | Undisclosed | Undisclosed | |
| Half Maximal Activity Concentration (AC50) | 12.19 | uM | Undisclosed | Undisclosed | Undisclosed | |
| Half Maximal Activity Concentration (AC50) | 3.981 | uM | Undisclosed | Undisclosed | Undisclosed | |
| Half Maximal Activity Concentration (AC50) | 8.627 | uM | Undisclosed | Undisclosed | Undisclosed |
Each Antibody-drug Conjugate Related to This Payload
Full Information of The Activity Data of The ADC(s) Related to This Payload
T-VCR 6b [Investigative]
Revealed Based on the Cell Line Data
| Experiment 1 Reporting the Activity Date of This ADC | [1] | ||||
| Efficacy Data | Half Maximal inhibitory Concentration (lC50) |
0.02۪.01 nM
|
High HER2 expression (HER2 +++) | ||
| Method Description |
Cells were seeded in 96-well plates at a density of 2000 cells/well for MDA-MB-231 cells and 5 000 cells/well for all the other cell lines and allowed to grow under normal oxygen conditions (20% O2). Cells were treated with the appropriate compound 24 h after plating and maintained at 37 °C under a humidified 5% CO2 and 20% O2 atmosphere. Cell viability was measured 72 or 120 h later with the WST-1 cell proliferation assay (Takara) according to the manufacturer's instructions. To represent the relative cell proliferation rate, results were normalized against the untreated condition.
Click to Show/Hide
|
||||
| In Vitro Model | Breast adenocarcinoma | SK-BR-3 cells | CVCL_0033 | ||